US20020068338A1 - Electroporation apparatus for control of temperature during the process - Google Patents
Electroporation apparatus for control of temperature during the process Download PDFInfo
- Publication number
- US20020068338A1 US20020068338A1 US09/957,891 US95789101A US2002068338A1 US 20020068338 A1 US20020068338 A1 US 20020068338A1 US 95789101 A US95789101 A US 95789101A US 2002068338 A1 US2002068338 A1 US 2002068338A1
- Authority
- US
- United States
- Prior art keywords
- electrodes
- electroporation
- cells
- receptacle
- pulse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004520 electroporation Methods 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title claims abstract description 34
- 230000008569 process Effects 0.000 title claims description 10
- 230000005684 electric field Effects 0.000 claims abstract description 38
- 239000012530 fluid Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 81
- 239000007943 implant Substances 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 238000004804 winding Methods 0.000 claims description 28
- 230000001276 controlling effect Effects 0.000 claims description 26
- 238000012545 processing Methods 0.000 claims description 23
- 238000013500 data storage Methods 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 8
- 239000004020 conductor Substances 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000005284 excitation Effects 0.000 claims 1
- 230000010349 pulsation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 53
- 210000003743 erythrocyte Anatomy 0.000 abstract description 7
- 239000013043 chemical agent Substances 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 3
- 210000001772 blood platelet Anatomy 0.000 abstract description 3
- 210000005260 human cell Anatomy 0.000 abstract description 3
- 239000002502 liposome Substances 0.000 abstract description 3
- 210000004962 mammalian cell Anatomy 0.000 abstract description 3
- 210000001938 protoplast Anatomy 0.000 abstract description 3
- 235000013601 eggs Nutrition 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 description 18
- 239000012528 membrane Substances 0.000 description 9
- 239000003990 capacitor Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
Definitions
- the present invention generally relates to electro-cell manipulation. More particularly, the invention concerns an electroporation apparatus and method for generating and applying an electric field to a material while controlling temperature of the process using a Peltier device for effective molecular introduction into cells and minimize damage to cellular tissue.
- a cell has a natural resistance to the passage of molecules through its membranes into the cell cytoplasm.
- scientists in the 1970s first discovered “electroporation,” where electrical fields are used to create pores in cells without causing permanent damage to them. Electroporation was further developed to aid in the insertion of various molecules into cell cytoplasm by temporarily creating pores in the cells through which the molecules pass into the cell.
- Electroporation has been used to implant materials into many different types of cells. Such cells, for example, include eggs, platelets, human cells, red blood cells, mammalian cells, plant protoplasts, plant pollen, liposomes, bacteria, fungi, yeast, and sperm. Furthermore, electroporation has been used to implant a variety of different materials, referred to herein as “implant materials,” “implant molecules,” “implant agents.” Namely, these materials have included DNA, genes, and various chemical agents.
- Electroporation has been used in both in vitro and in vivo procedures to introduce foreign material into living cells.
- a sample of live cells is first mixed with the implant agent and placed between electrodes such as parallel plates. Then, the electrodes apply an electrical field to the cell/implant mixture.
- Examples of systems that perform in vitro electroporation include the Electro Cell Manipulator ECM 600 product, and the Electro Square Porator T820, both made by the BTX Division of Genetronics, Inc. In San Diego, Calif.
- Electro Square Porator T820 made by Genetronics, Inc.
- U.S. Pat. No. 5,442,272 teaches of a quick connect suction electrode assembly for electroporation that includes a temperature regulating element. However, there is no suggestion to integrate temperature control with an electroporation control for efficient and effective implant material processing.
- U.S. Pat. No. 5,185,071 teaches of a programmable electrophoresis apparatus using temperature controlling Peltier devices attached to the sides of a buffer chamber. This disclosure teaches only of electrophoresis applications.
- the electric field may actually damage the electroporated cells in some cases.
- an uncontrolled electric field and generated heat may damage the cells by creating permanent pores in the cell walls.
- the electric field may completely destroy the cell caused by overheating during an electroporation event.
- existing electroporation systems may not be suitable for certain applications due to imprecise temperature control of implant agent materials and host cells during electroporation.
- many existing electroporation systems lack sufficient control over the parameters of the electric field pulses such as amplitude, duration, number of pulses during this process while simultaneously controlling the temperature of the implant materials.
- the present invention concerns an electroporation method and apparatus for generating and applying an electric field while controlling temperature according to a user-specified control scheme.
- An exemplary electroporation temperature controlling receptacle device includes a cuvette, a holder and a Peltier device for controlling temperature, the receptacle is configured for either static or flow conditions.
- the invention also provides for integrated control of the electric field for electroporation to move the molecule into the cell while controlling temperature of the implant agent and host cellular material.
- the implant agent molecular material may be genes or drugs such as DNA, portions of DNA, chemical agents or any other molecule. The molecular material is placed in close proximity to the cells in a fluid medium containing the cells.
- one aspect of the present invention concerns a method of generating and applying an electric field according to a user-specified temperature control scheme integrated with an electroporation pulsing scheme for more efficient introduction of implant agents into cells and minimize damage to the cellular material.
- the present invention provides a number of distinct benefits.
- the invention is useful to introduce molecules of an implant agent into cells with significantly increased effectiveness.
- the implant agent for example, may include drugs for treating cancer, kaposi's sarcoma, and a number of other diseases and conditions.
- the invention increases the efficacy of the agent. Consequently, less of the implant agent is needed, thereby being more economical.
- the invention also provides a number of other benefits, as discussed in greater detail below.
- FIGS. 1A, 1B, 1 C, 1 D, 1 E and 1 F are diagrams illustrating various features of an electroporation cuvette and flow through chamber holders that include Peltier devices for temperature control for a contained or flow-through condition during the electroporation process.
- FIG. 2A and 2B show the electroporation and temperature control hardware and interconnections to the receptacle holders in perspective and block diagram form pursuant to the present invention
- FIG. 3 is a diagram illustrating an electroporation waveform known in the art
- FIG. 4 is a diagram of an exemplary hardware components and interconnections of an electroporation pulse controller and generator subsystem pursuant to one aspect of the present invention
- FIG. 5 is a diagram of an exemplary article of manufacture, comprising a data storage medium, in accordance with one aspect of the present invention
- FIG. 6 is a flowchart illustrating an exemplary sequence of method steps in accordance with one aspect of the present invention.
- FIG. 7 is a drawing illustrative of an electroporation pulse, pursuant to the invention.
- FIGS. 8 - 11 are drawings of illustrative electroporation pulsing schemes with temperature control, pursuant to the invention.
- FIG. 12 is a flowchart illustrating an exemplary sequence of method steps in accordance with one example of the present invention.
- one aspect of the present invention concerns an electroporation apparatus and method for processing implant agents into cells by generating and applying an electric field to these materials while controlling temperature during the processing with a user selected control scheme of temperature for efficient and effective introduction of these materials to minimize damage to cellular tissue.
- Precision temperature control of the processing is provided by an integrated Peltier device with the electroporation apparatus using processor control.
- FIG. 1A illustrates a first preferred exemplary embodiment of the invention showing in cross-section a cuvette 5 which is a receptacle for both host cells and implant materials undergoing electroporation.
- FIG. 1B illustrates an alternate exemplary embodiment using a flow through cuvette 5 a, which comprises a clear plastic rectangular housing defining an enclosure 9 having a round opening at the upper end. This is similarly taught in U.S. Pat. No. 5,676,646
- Flow Through Electroporation Apparatus which is incorporated by reference. Both of these receptacles can be in disposable-form.
- An example of the cuvette 5 is BTX brand cuvette, model number 640 made by Genetronics, Inc. of San Diego, Calif.
- the cuvette 5 is portable and can be insertable into a cuvette holder 10 .
- the cuvette holder 10 is a platform, which supports the cuvette 5 for electroporation processing and electrically interfaces with electroporation and temperature controller 100 .
- This opening is closed by a push-on plastic cap 9 .
- the tubing segment 130 extends snugly through a hole in the middle of the cap 9 at one end of the chamber.
- the tubing segment 132 extends through a hole in the lower end of the enclosure 2 which is sealed with a fitting 6 .
- the enclosure 2 is preferably molded with a pair of embedded elongated electrodes 7 and 8 which that interface with the electrodes 40 , 42 of the holder in a preferred form that carry the electrical signal from the electroporation and temperature control assembly 100 .
- the electrodes 7 and 8 are uniformly spaced apart and extend parallel, substantially the full length of the receptacle 5 a, between the inlet and outlet to enable fluid to pass therebetween.
- the electrodes ( 7 and 8 ) and ( 40 and 42 ) may be of any suitable conductive material such as stainless steel or aluminum and may be gold plated.
- the holder 10 in exemplary form is an electrically insulated platform with terminals for connecting at least two independent conductors 11 , 13 for supplying the electrical energy for both the electroporation pulses and causing the Peltier devices 44 to transfer heat energy to or from the receptacle and holder assembly 20 .
- the holder device 10 is typically made of delrin or other nonconducting material with a screw clamping member for placement of a cuvette 5 or 5 a in the holder 10 .
- the electrodes 7 , 8 preferably interface with a pair of electrodes 40 , 42 attached to the holder 10 , but can be integrated in a single unit if required.
- Such a cuvette holder without components for regulating temperature is a BTX brand Safety Stand model 630 -B made by Genetronics, Inc. of San Diego, Calif.
- a holder can also include an electrical safety interlock feature incorporated into a hood covering member to prevent electrical shock to personnel when operated.
- the holder 10 preferably uses a plate-shaped electrodes 40 , 42 with Peltier devices 44 incorporated therein that allows for rapid heating or cooling of host and implant materials in the cuvette.
- the Peltier device 44 contained in the electrodes 40 , 42 control temperature of materials undergoing electroporation.
- the holder preferably includes a temperature sensor 58 (FIG. 2B) that is attached to or in close proximity to materials undergoing electroporation.
- the temperature sensor 58 can be attached to the holder 10 for maintaining close proximity to the cuvette during processing to provide closed-loop processing temperature control in real-time.
- the temperature sensor 58 can be, for example an infrared temperature sensor that is attached to a hood member of the holder 10 such that when closed, accurate temperature measurement of the material undergoing electroporation is achieved.
- the receptacle receives cellular and implant materials for in vitro use, the materials are cells and implant agent materials placed in either form of the cuvette 5 or 5 a.
- the operation entails having a technician inject a liquid implant agent by pouring, eye-dropping, or otherwise introducing the agent into the cuvette using automated equipment for dispensing these materials.
- FIG. 1C illustrates another embodiment of the receptacle device in a flow-through chamber 54 form.
- This receptacle device is taught in U.S. Pat. No. 5,676,646 entitled “Flow Through Electroporation Apparatus,”. except for the means for controlling temperature of the materials.
- the chamber 54 receptacle device receives cellular and implant materials for in vitro use by withdrawing fluids from a reservoir or human for processing during transmission.
- the flow through receptacle and holder unit 20 comprises a rectangular outer housing 57 which encloses an elongated flow through chamber 54 .
- It includes a pair of uniformly spaced apart elongated electrodes in the form of a cylindrical conductive rod 55 concentrically mounted with a cylindrical vessel 57 defining opposed parallel electrode surfaces.
- the rod 55 and vessel 57 are made of stainless steel and may be gold plated where desired.
- the ends of the electrode surface forming rod 55 and vessel 57 are mounted in hollow blocks 59 and 61 of insulating, plastic material and sealed with high temperature elasticomeric O-rings 63 .
- the O-rings are seated within circular groves machines inside the blocks 59 and 61 . They are preferably made of a high temperature resistant material such as that sold under the trade mark of VITON.
- the blocks 59 and 61 have cylindrical holes bored therein for receiving the ends of the rod 55 and vessel 57 .
- the blocks 59 and 61 have inlet and outlet ports, 65 and 67 , respectively formed therein so that the mixture of a blood and fluid medium can pass through the flow through chamber between the opposed electrodes as indicated by the arrows (FIG. 1C).
- Fittings 71 and 72 (FIG. 2A) are screwed into the threaded walls of the inlet and outlet ports at 65 and 67 for coupling tubing segments 74 and 76 thereto.
- the tubing segments 74 and 76 extend within the housing 52 and are in turn connected to fitting 78 and 80 mounted on the front panel of the housing.
- the tubing segments 130 and 132 are connected to the fittings 78 and 80 , respectively.
- the electric cables 136 and 138 (FIG. 2A) from the electroporation and temperature subsystem 100 have plugs that are removably connected to jacks 82 and 84 on the front panel of the housing 52 of the flow through chamber unit. These jacks are in turn connected to wires 86 and 88 which connect to threaded shaft and nut electrode assemblies 40 or 42 (FIG. 1C) as one electrode and to a clamp around vessel 57 as the other electrode of the flow through chamber 54 .
- the electrode nut assembly 40 and 42 provide an electrical connection to the rod electrode 55 while the assembly 42 provides an electrical connection to the vessel electrode 57 .
- the Peltier devices 44 are mounted to the external ends of the nut electrode structures 40 and 42 .
- FIG. 1D shows another embodiment of a flow through chamber receptacle holder 101 that can be used with a peristaltic pump (not shown) with an input receiving tube 110 .
- This flow through electroporation chamber receptacle includes a safety stand 116 , having a generally U-shaped configuration with a slot 118 for receiving the disposable chamber formed between opposing sides, or thermally conducting panels 120 and 122 .
- the side panel 122 is provided with upper and lower slots 124 and 126 , respectively, for receiving the fluid or tubes 110 and 128 connected to the chamber.
- FIG. 1E shows the chamber, within which, the materials undergoing electroporation pass through comprises a central generally rectangular bar-shaped body member 128 having an elongated centrally disposed through slot 130 formed therein as shown in FIG. 1D.
- the slot 130 is enclosed on opposite sides of the bar-shaped body member 128 by means of a pair of bar shaped electrodes 40 and 42 .
- the central body member 128 is preferably constructed of a nonconductive material whereas the bar electrodes 40 and 42 are preferably constructed of conductive material that can easily be gold-plated, at least along the surfaces, in communication with the sides of the slot.
- the electrode 134 is provided with upper and lower tube connections for attachment of the tubes 110 and 128 for opening communications directly with the upper and lower ends, respectively, the slot 130 .
- the flow through chamber receptacle is assembled with the electrodes 40 and 42 with Peltier devices 44 , sealingly engaging opposite sides of the bar 128 enclosing the slot 130 .
- the electrodes are preferably, sealingly bonded by suitable means to the opposite sides of the central bar member.
- the assembled chamber then slides into the open slot 118 in the safety stand 116 between a pair of opposing spring contacts 136 and 138 .
- These contacts are of a suitable conductive material, such as a copper alloy and are mounted in conductive holders 140 and 142 , which are in turn attached to conductive cables.
- FIG. 1F shows the electrical cables in a top view 144 and 146 pass or extend through an opening 166 having a gromit 168 in the backplate 152 .
- a pair of conductive cables, 144 and 146 include leads 148 and 150 connected such as by soldering to the respective holders 140 and 142 .
- Spring contacts 136 and 138 may have any suitable construction, but in a preferred form is constructed to have a somewhat louvered configuration for proper thermal contact.
- a blower unit can also be incorporated if required.
- Variations of the cuvette can be use of a concentric annular electrode structure wherein a center electrode would be at the center of the cuvette and an outer electrode would be on the surface of the cuvette.
- a variation of the holder 10 would include an electrode that attaches through the top center and center of the cuvette with an outer electrode interfacing with the cuvette which would contain the Peltier device 44 .
- At least one Peltier device must be incorporated with the cuvette 5 or 5 a and corresponding holder 10 .
- the electrodes 40 , 42 provide heat flow control using the integrated Peltier device in each of the electrodes.
- An electrical pulsing field is placed across the material between electrodes 40 , 42 as discussed above in the receptacle and holder assemblies 20 .
- the electrode structures 40 , 42 of these above embodiments receive electrical input from a separate power control 201 (FIG. 2B). Wires with low resistance are used to make the connection to electrodes 40 , 42 .
- An electrical field is formed between electrodes 40 , 42 structures within the receptacle when the power supply is controllably turned on from the subsystem 100 to provide a pulsing electric field across the materials undergoing electroporation. Control of the electroporation pulsing scheme by an electric field which varies in both magnitude and duration improves transfection of gene material.
- the preferred electroporation pulsing scheme is taught in U.S. patent application Ser. No. 08/709,615, entitled “Electroporation User Configured Pulsing Scheme,” which is hereby incorporated by reference.
- the present invention provides temperature control of the material that is undergoing electroporation which naturally warms or cools the materials contained within the receptacle when electric fields are transmitted therethrough.
- the receptacle and holder assembly 20 is equipped with a Peltier device 44 for the temperature control during the electroporation process.
- the Peltier device 44 is electrically and thermally junctured at the electrodes 40 , 42 .
- Peltier device 44 receives current from an external, feedback regulated power supply forming part of the subsystem 100 .
- the Peltier device 44 controls temperature within ⁇ 0.1C. Controlling material temperature during the electrical pulsing electroporation treatment provides an improved material yield.
- FIG. 2A shows an exemplary application of the apparatus that is used with a peristaltic pump (not shown), and injection pump (not shown), a flow through receptacle chamber receptacle assembly 89 and the electroporation and temperature control subsystem 100 .
- a peristaltic pump not shown
- injection pump not shown
- a flow through receptacle chamber receptacle assembly 89 and the electroporation and temperature control subsystem 100 .
- the apparatus includes a pair of electric cables for connecting the subsystem 100 with the flow through receptacle assembly 89 .
- FIG. 2B illustrates a block diagram showing the components for controlling the pulsing field magnitude, field duration and temperature control of the cuvette holder 10 with receptacle device.
- the Peltier device 44 forms part of the electrode structures for receiving electrical input from temperature control block 56 .
- the Peltier device transfers heat from the adjacent material within the receptacle to its external surface within the assembly 20 .
- a temperature sensor may be used to communicate with the material undergoing electroporation to provide feedback signals to temperature control 56 .
- Temperature sensor 58 which can be an infrared type sensor, receives temperature readings from the material in the electroporation cuvette holder device 10 and sends corrective signals to temperature control block 56 which then responds with an appropriate electrical signal to Peltier device 44 .
- Temperature control block 56 functions to send an output electric signal to device 44 in response to temperature sensor input.
- the output of temperature sensor 58 is fed into an amplifier.
- the amplifier can be contained within the analog portion of the temperature controller 56 .
- a comparator which receives the amplified signal and which functions to compare the amplified signal with an operator-initial or a reference signal sent through a digital-to-analog converter to the comparator. When the temperature is above the reference, the output from the comparator forward biases a power transistor with ratings of less than 100 amps and 100 volts which is connected in series with the Peltier device 44 , thereby allowing cooling of materials in the cuvette or flow through receptacle.
- heating can occur by reversing directional current through the Peltier device 44 by having a symmetrical connected type circuit attached to the electrode structures.
- an amplified signal from temperature sensor 58 is sent to an analog to a digital converter and is used for reporting. This signal could, however, also be used for control through the user's program.
- Temperature control 56 is regulated by control board 60 that is digital-based. The control board 60 interfaces to the analog-based control 56 via analog/digital converter 62 and digital/analog converter 64 (FIG. 2B).
- Control board 60 functions to control temperature of the material undergoing electroporation.
- the control board 60 receives its program from a controller 66 and, once the program is entered, the keyboard and the computer are no longer necessary.
- Programming can be in computer languages such as C or BASIC (registered trade mark) if a personnel computer is used for the controller or assembly language if a microprocessor is used for the controller 66 .
- a user specified control of temperature is programmed in the controller 66 .
- the controller 66 may comprise a computer, a digital or analog processing apparatus, programmable logic array, a hardwired logic circuit, an application specific integrated circuit (“ASIC”), or other suitable device.
- the controller 66 may comprise a microprocessor accompanied by appropriate RAM and ROM modules, as desired.
- the controller 66 is coupled to a user interface 50 for exchanging data with a user.
- the user may operate the user interface 50 to input a desired pulsing pattern and corresponding temperature profile to be applied to the electrodes 40 , 42 and Peltier device 44 .
- the voltage polarity controls direction of heat flux to or from the receptacle device and current output to the Peltier device 44 can be either, amplitude or pulse width modulated for precision heat flux control.
- the user interface 50 may include an alphanumeric keypad, touch screen, computer mouse, push-buttons and/or toggle switches, or another suitable component to receive input from a human user.
- the user interface 50 may also include a CRT screen, LED screen, LCD screen, liquid crystal display, printer, display panel, audio speaker, or another suitable component to convey data to a human user.
- Controller 66 used for inputting and outputting signals to control board 60 may be any type of ASCII terminal having an RS-232 or RS-485 port.
- the control board which receives input from the computer and produces outputs can include an 8052 -AH-BASIC microprocessor (8 Kb BASIC ROM, a programmable pulse generator, built-in algorithm using EEPROMs and EPROMs) 8 Kb of RAM, 8 Kb of battery-backed RAM, battery-backed real-time clock and timer with 0.005 sec resolution, 8 Kb of ROM command extensions, 8 Kb of EEPROM, 24 bits of programmable digital input-output, and an RS/232 printer port with a programmable Baud rate.
- an 8052 -AH-BASIC microprocessor 8 Kb BASIC ROM, a programmable pulse generator, built-in algorithm using EEPROMs and EPROMs
- 8 Kb of RAM 8 Kb of RAM
- battery-backed RAM battery-backed real-time clock and timer with 0.005 sec resolution
- 8 Kb of ROM command extensions 8 Kb of EEPROM
- 24 bits of programmable digital input-output and an RS/232 printer port with
- Control board 60 functions to receive controller 66 input and is driven by the power supply 70 .
- Power supply 70 is a switching type which can have the following typical outputs: 12 volts with up to 20 amp output to the Peltier device 44 , the RS-232 or RS-485 port, the digital to analog converters 62 and 64 , and temperature control block 56 .
- Power supply 70 also provides ⁇ 12 volts, 0.25 amps for the RS-232 port and the temperature control block. Additionally, power supply 70 would typically supply 5 volts and one amp to the control board 60 and the temperature control 56 .
- Electroporation Pulsing Subsystem [0053] Electroporation Pulsing Subsystem
- FIG. 3 shows a pulsing scheme for electroporation as known in the art.
- Prior electroporation power supplies used electromechanical relay to provide consecutive e first and second pulses, see S. I. Sukharev et al., Biophys. J. Vol. 63, November 1992, pp. 1320-1327. More particularly, Sukharev uses an electric field pulse 101 .
- the pulse scheme 101 includes (1) a first, narrow duration, high voltage pulse 102 , ( 2 ) a delay 103 of ⁇ t, during which no pulse is generated, then (3) a second, wide duration, low voltage pulse 104 .
- the first pulse 102 was intended to porate the membrane, whereas the second pulse 104 was intended to electrophorese DNA into the cell cytosol.
- Sukharev recognized that the delay 103 should not be excessive.
- Sukharev Although the Sukharev system may provide satisfactory results in some applications, this system may not be completely adequate for certain other applications. Some users may find, for example, that Sukharev's electroporation does not effectively move enough molecules of the implant agent into the target cells. This results from an excessive delay 103 between Sukharev's first 102 and second 104 pulses, as recognized by the present inventor.
- the pores of a cell, created by electroporation, stay open for a finite time, largely depending upon the cell's temperature. Thus, the effect of the first pulse may start to significantly decay (thereby closing the cell's pores) during the delay between the first and second pulses.
- Electroporation Power Supply [0057] Electroporation Power Supply
- FIG. 4 shows the pulsing electroporation power subsystem 200 which receives an input voltage, such as 110V or 220 VAC, from a power source 203 .
- the subsystem 200 includes a comparable apparatus, which is disclosed in U.S. patent application Ser. No. 08/709,615 and entitled “Electroporation User Configured Pulsing Scheme.”.
- the subsystem 200 has an electroporation power supply 202 and driver control 204 which controls or changes voltage magnitude, switch on or off, invert voltage polarity or provide voltage pulsing from the power supply 202 to electrodes 40 , 42 . Signals from control board 60 control provide the desired voltage or current output.
- a power supply 202 provides a reliable source of desired voltage levels for use by the electroporation power control 201 .
- An example of such a source is available, for example, from Electro Square Porator T 820 , made by the BTX Division of Genetronics, Inc.
- Either independent from or associated with power supply 70 is an electroporation power supply 202 which produces sufficient voltage range, preferably up to 500 volts.
- the divider 204 converts the input voltage into multiple reference voltages. In the illustrated embodiment, reference voltages of 500 V (D.C.) reside on the divider output lines 204 a - 204 b.
- These voltages are provided to collectors 206 b - 207 b of first and second respective transistors 206 - 207 .
- the transistors 206 - 207 are selectively gated to apply their input voltages to step voltage nodes 208 - 209 .
- the selective gating of the transistors 206 - 207 is performed by respective comparators 212 - 213 , which trigger gates 206 a - 207 a of the transistors 206 - 207 when voltages at the step voltage nodes 208 - 209 dips below voltages established on step voltage input lines 216 - 217 .
- the comparator 212 determines that the voltage on the step voltage node 208 is less than the voltage on the preset input line 216 , the comparator 212 activates the gate 206 a of the transistor 206 , causing the transistor 206 to couple the input voltage of the divider 204 directly to the step voltage node 208 .
- the transistors 206 maintain substantially constant voltages at the respective step voltage nodes 208 - 209 in accordance with the step voltage input lines 216 - 217 .
- the subsystem 200 also includes energy reservoirs 220 - 221 coupled to respective step voltage nodes 208 - 209 .
- Exemplary energy reservoirs 220 - 221 may comprise capacitors, such as 3200 ⁇ F, 500 V electrolytic capacitors. These capacitors are appropriate for maximum step voltages 208 - 209 of 500 V (D.C.).
- the subsystem 200 also includes a transformer 224 , which includes a primary winding 224 a and a secondary winding 224 b.
- the transformer 224 preferably is designed with low leakage inductance characteristics to provide a fast pulse rise time, i.e., several microseconds.
- the transformer 224 exhibits low inductance, on the order of a few ⁇ H.
- These features may be provided by winding the transformer 224 with a single cable of twelve separate, twisted conductors of which six are connected in parallel for the primary, six are connected in series for the secondary. This provides a 1:6 step-up ratio.
- a separate low voltage D.C. bias winding around the core may be used to employ the full flux swing of the transformer's core.
- the transformer may utilize a core made of laminated iron.
- the transformer 224 may advantageously be constructed to saturate if the pulse length exceeds a maximum prescribed value, thereby protecting a patient from excessive electrical energy.
- the transformer 224 is capable of carrying 0.3 V-sec (3000 V ⁇ 100 ⁇ sec) before saturation.
- Another advantage of the transformer 224 is that its output is floating, and no substantial current will flow if the patient is connected to ground potential.
- the secondary winding 224 b is coupled to output connection nodes 230 - 231 , which preferably connect to the cuvette holder device 10 .
- the load between the electrodes 40 , 42 is represented by the in vitro implant agents and host material in the cuvette holder 10 which may contain platelets, human cells, red blood cells, mammalian cells, plant protoplasts, plant pollen, liposomes, bacteria, fungi, yeast, sperm, or other cells.
- a diode 236 may be placed between the energy reservoir 220 and the connection 230 .
- a diode 237 may be placed between the secondary winding 224 b and the connection 230 .
- the subsystem 200 also includes switches 226 - 227 to selectively enable current to flow through the primary and secondary windings 224 a - 224 b, respectively.
- each switch 226 - 227 may comprise an insulated gate bipolar transistor (“IGBT”), such as a Fuji Electric brand IMBI400F-060 bmodel IGBT.
- IGBT insulated gate bipolar transistor
- the switch 226 and the energy reservoir 221 are coupled in series, this series combination being attached in parallel with the primary winding 224 a.
- the collectors 226 b and emitter 226 c are electrically connected.
- the energy reservoir 221 is effectively placed in parallel with the primary winding 224 a . This allows current from the energy reservoir 121 to flow through the primary winding 224 a.
- the switch 227 and energy reservoir 220 are coupled in series, this series combination being attached in parallel with the secondary winding 224 b .
- the collectors 227 b and emitter 227 c are electrically connected.
- the energy reservoir 220 is effectively placed in parallel with the secondary winding 224 b. This allows current from the energy reservoir 220 to flow through the electrodes 40 , 42 .
- none of the energy reservoirs 220 - 221 or switches 226 - 227 grounds the windings 224 a - 224 b .
- the windings 224 a - 224 b therefore electrically float. As a result, no substantial current will flow through a patient or other load 234 that is connected to another earth or ground potential.
- Electroporation Pulse Controller [0072] Electroporation Pulse Controller
- the controller 66 114 (FIG. 2) regulates the on-times and off-times of the switches 226 - 227 in accordance a specified schedule, thereby generating a predetermined pulsing scheme at the electrodes 40 , 42 .
- the control 201 triggers the switch 227
- the voltage of the energy reservoir 220 is applied to the electrodes 40 , 42 .
- the control 201 triggers the switch 226
- the voltage of the energy reservoir 220 is applied to the transformer 224 , where it is multiplied by six and applied to the connections 230 - 231 .
- the controller 66 (FIG. 2B) may also trigger both switches 226 - 227 to apply an additive voltage, comprising the sum of the step voltages 208 - 209 , to the electrode structures 40 , 42 .
- the electrical requirements can be derived from the field strength, which was determined efficacious from in vitro experiments with tumor cells and drugs, typically 1200-1300 V/cm, and a pulse length of about 100 ⁇ sec.
- the maximum voltage of the generator derives from the maximum cavity size used.
- the internal impedance of the generator should be at least a factor 10 lower than 22 Ohm so that no substantial drop in voltage occurs between charging and delivered voltage. With the maximum voltage of 3000 V and a load impedance of 22 Ohm, the switching requirements from a partial capacitor discharge to generate a square pulse are a very substantial 400 kW.
- the desired maximum permeation pulse length is 100 ⁇ sec; this results in an energy per pulse of 40 J.
- a maximum voltage of 500 V and maximum pulse length of 200 msec may be used.
- the switches 226 - 227 can preferably maintain continuous current 800 A for one msec.
- the maximum voltage is 600 V.
- Transient spikes are limited to a maximum of 550 V for a 10% safety margin. This required careful low inductance mechanical assembly to reduce transients and to be able to get as close as safely feasible to the maximum voltage limit of the IGBT.
- the load impedance of 22 Ohm is transformed to the primary: 22/6 ⁇ 6 ⁇ 0.61 Ohm.
- a total internal impedance of 0.055 Ohm was achieved on the primary side of the transformer, which translates to an equivalent impedance of 1.98 Ohm on the secondary.
- the IGBT can be configured to contain a current limiting feature, which turns the switch off within a few ⁇ sec in case of excessive load currents which might happen if an arc or a short circuit condition occurs.
- the necessary capacitor size can be estimated from the maximum allowable voltage drop across the load of 5%.
- the energy stored in these capacitors is 400 Joule.
- a second capacitor discharge circuit delivers the longer pulse lengths (several 100 msec) and low voltage (500 V) without the pulse transformer.
- the low voltage circuit and the high voltage circuit are decoupled from each other by stacks of diodes 237 and 236 .
- a different aspect of the invention broadly concerns a method for generating a user-specified electric field pulsing pattern to achieve improved electroporation.
- This method may be implemented, for example, by operating the controller 66 to execute a sequence of machine-readable instructions. These instructions may reside in various types of data storage media.
- one aspect of the present invention concerns an article of manufacture, comprising a data storage medium tangibly embodying a program of machine-readable instructions executable by a digital data processor to perform method steps to generate a user-specified electric field pulsing pattern to achieve improved electroporation.
- This data storage medium may comprise, for example, RAM contained within the controller 66 .
- the instructions may be contained in another data storage medium, such as a magnetic data storage diskette (FIG. 5). Whether contained in the controller 66 or elsewhere, the instructions may instead be stored on another type of data storage medium such as DASD storage (e.g., a conventional “hard drive” or a RAID array), magnetic tape, electronic read-only memory (e.g., ROM), optical storage device (e.g., WORM), paper “punch” cards, or other data storage media.
- DASD storage e.g., a conventional “hard drive” or a RAID array
- magnetic tape e.g., magnetic tape
- electronic read-only memory e.g., ROM
- optical storage device e.g., WORM
- paper “punch” cards e.g., paper “punch” cards, or other data storage media.
- FIG. 6 shows a sequence of method steps 400 to illustrate one example of this aspect of the present invention.
- the sequence of FIG. 6 is described in the context of the subsystem 200 described above.
- the controller 66 in task 404 receives user input specifying an output pulse pattern of one or more output pulses.
- this user input may be received from the user interface 50 .
- the user input may be received from another electronic device, or even a prestored record.
- the user input specifies a duration for each pulse and also specifying either a “high” output voltage or a “low” output voltage.
- the pulse generator in task 404 generates the “low” predetermined voltage at the output terminals 230 and 231 for the specified duration. More particularly, the controller 66 may generate a low voltage pulse by gating the switch 227 , thereby permitting the energy reservoir 220 to discharge through the electrodes 40 , 42 .
- high voltage pulses are generated at the secondary winding terminals by concurrently applying another voltage to the primary winding terminals of the transformer for the specified duration. More particularly, the high voltage pulse involves generating the voltage as discussed above, while concurrently triggering the switch 226 to permit the energy reservoir 221 to discharge through the primary winding 224 . As the voltage of the reservoir 221 is multiplied by the transformer 224 , a high voltage is created at the electrodes 230 - 231 . This voltage is the additive sum of the voltages stored in the energy reservoirs 220 - 221 . Alternatively, a lesser “high” voltage output may be created solely by triggering the switch 226 , without involving the switch 227 .
- One or more of the above-mentioned pulses are therefore generated in task 404 to produce the user-specified pulse pattern.
- the routine 400 ends in task 406 .
- the pulse subsystem 200 provides a user-specified pulse pattern comprising one or more pulses of “high” and/or “low” output voltage.
- FIGS. 8 - 11 illustrate various exemplary pulse shapes, which may be used alone or in combination to constitute the user-specified pulsing scheme with associated temperature profile in real-time for processing of materials.
- the time scale is not necessarily linear as shown since the pulsing event occurs temporally in microseconds and cooling and heating of materials is an extrinsic factor of the apparatus used depending upon the receptacle device's volume for containing the materials and thermal design for effectuating heat transfer into or out of the receptacle device.
- each of the pulsing patterns of FIGS. 8 - 11 may provide distinct advantages for different applications, the following description highlights the features and operation of a pattern 700 (FIG. 9) to illustrate the operation of the invention, both in the electroporation pulse scheme and temperature control in real-time.
- the polarity and current, which can be pulse width modulated, through the Peltier device 44 directly correlates with temperature in the receptacle device.
- temperatures are typically around four degrees centigrade at the lower extreme and can be warmed to around 40 degrees centigrade. Desired material temperatures associated with electroporation pulsing in real time of particular cells and implant agents is functionally related to the type of cells and implant materials used and the desired outcome of the processing.
- Such control can be user specified and stored in a programmable form on a data storage media such as that shown in FIG. 5 and be implemented using the electroporation and temperature controller 100 .
- the pattern 700 comprises a “stepped pattern,” in that it provides first, second, and third voltage levels 702 - 704 . One, two, or all of these voltages may be the same, if desired.
- the pulses have first, second, and third durations 706 - 708 .
- the first and third voltages 706 , 708 provide a 500 V (D.C.)
- the second voltage 707 provides 3000 V (D.C.).
- the user may specify a desired magnitude of electric field to be applied by the transformer 224 , and a measurement of the gap between the electrodes 40 , 42 .
- the controller 66 may compute the appropriate voltage for the transformer 224 to generate in order to apply the desired electric field, for example by multiplying the electric field by the gap.
- the gap measurement may be input by the user manually.
- the gap may be mechanically measured and electronically fed to the controller 66 by automated means such as shown in U.S. Pat. No. 5,439,440, which is hereby incorporated by reference in its entirety.
- the efficiency of the implant agents to cells during electroporation processing is significantly dependent on the duration of cellular membrane permeabilization which has been discovered to be directly dependent on the temperature prior to, during and after pulsing application.
- Cellular permeability is modifiable by temperature changes. By raising the temperature, the permeability of the cellular wall is lowered. The lowering the ambient material temperature causes the permeability of the cellular material to increase.
- temperature should be lowered to around ice cooled temperatures, e.g., 4 degrees centigrade. After pulsing, usually several minutes, the temperature of the materials should be raised to around 40 degrees centigrade to seal and anneal the cellular membrane.
- some cellular materials are very sensitive to temperature and cannot survive extreme temperature changes. In such cases, cellular manipulations need to be carried out at the optimal cell survival conditions.
- the corresponding temperature profile in real time would exist and be controlled by the Peltier device 44 in the materials undergoing electroporation.
- the causal relationship of temperature effects when materials undergo electroporation has been studied and demonstrated that cellular membrane alterations do occur under varying temperature and electrical fields. In particular, this is taught in an article entitled “Studies on Electroporation of Thermally and Chemically Treated Human Erythrocytes,” by Nanda et al. in Bioelectrochemistry and Bioenergetics, 34 (1994) 129-134.
- Temperature is a significant factor during electroporation processing of cells such as red blood cells with implant agents. When temperature increases during electroporation processing, effectiveness is significantly reduced. For example when using red blood cells, Increase in the temperature during electroporation from four to forty-three degrees Centigrade reduces electroporation efficiency by approximately 50%. Post pulse incubation of red blood cells at higher temperatures further reduces the electroporation effectiveness.
- FIG. 12 describes an illustrative sequence 2000 involved in generating and applying the step pattern 700 , and the effects caused by application of the pattern 700 with corresponding control of temperature.
- the user interface 50 receives user input in task 1004 .
- the user input includes the user's specification of a desired electroporation pulsing pattern, including a duration and voltage level for each pattern portion and the corresponding control of temperature.
- the power supply 202 Concurrently with task 1004 , the power supply 202 generates the reference voltages at the output nodes 208 - 209 .
- the reference voltages 208 - 209 of 500 V (D.C.) are used.
- Generation of the reference voltages in task 1008 charges the energy reservoirs in task 1008 .
- an operator in task 1010 inserts molecules of an implant agent to the receptacle device for processing.
- the implant agent may comprise one or more types of DNA, genes, and/or various chemical agents.
- Step 1010 places the implant agent between the interstices of the cells at the process site.
- the Peltier device 44 cools the materials in the receptacle device to around ice temperatures for most processing applications. However, warming of materials undergoing processing can be implemented.
- the controller 66 in task 1014 gates the switch 227 , discharging the energy reservoir 220 , thereby applying the “low” voltage to the electrodes 40 , 42 .
- This step accumulates molecules of the implant agent near the membranes of the cells in the cell sample. As discovered by the present inventors, this step may be adequately performed with a reduced voltage.
- the “low” voltage of the energy reservoir 220 achieves this purpose, while still avoiding damage to the cells in the sample and saving electrical energy.
- FIG. 9 illustrates task 1014 as the voltage pulse 702 .
- this pulse preferably comprises a square wave having a duration 706 of about 10-200 msec and a voltage of about 500 V (D.C.).
- D.C. 500 V
- different parameters may be substituted to define the pulse 702 .
- a corresponding cooling period occurs to allow greater permeability of cellular materials undergoing processing.
- FIG. 9 illustrates this step as the voltage pulse 703 .
- this pulse preferably comprises a square wave having a duration 707 of about 100 ⁇ sec and an electric field magnitude of about 1200 V/cm. Depending upon the application, however, different parameters may be substituted to define the pulse 702 .
- the temperature is maintained at the cool state during processing to maintain high permeability of a cellular membrane undergoing processing.
- the subsystem 200 automatically limits damage to cells of the tissue sample during this step.
- the voltage from the primary winding 224 a saturates the secondary winding 224 b
- the voltage presented by the secondary winding 224 b begins to decay, in accordance with known principles of transformer operation.
- the secondary winding 224 b automatically limits the tissue sample's exposure to this high voltage pulse.
- the controller 66 ceases gating of the switch 226 while continuing to gate the switch 227 . This step permits the molecules of the implant agent to transit the cells' permeable membranes, and enter the cells' cytoplasm.
- FIG. 10 illustrates this step as the voltage pulse 704 .
- this pulse preferably comprises a square wave having a duration 708 of about 1-200 msec and a voltage of about 500 V (D.C.).
- D.C. 500 V
- different parameters may be substituted to define the pulse 704 .
- the controller 66 releases gating of the switch 227 , ending the pulse 700 .
- the Peltier device 44 either warms or cools the material in the receptacle device in task 1022 , and the sequence 2000 ends in task 1024 .
- This step normally takes on the order of several minutes where it is either desirable to leave the cellular membrane open (keeping material cool) or sealing or annealing the cellular membrane (keeping the material warm).
Abstract
An electroporation method and apparatus generating and applying an electric field according to a user-specified pulsing and temperature profile scheme. The apparatus includes a cuvette holder with a Peltier device forming part of the electrode structures that form part of the holder. Advantageously, one such pulse includes a low voltage pulse of a first duration, immediately followed by a high voltage of a second duration, immediately followed by a low voltage of a third duration. The low voltage electroporation field accumulates molecules at the surface of a cell, the appropriately high voltage field creates an opening in the cell, and the final low voltage field moves the molecule into the cell. The molecules may be DNA, portions of DNA, chemical agents, the receiving cells may be eggs, platelets, human cells, red blood cells, mammalian cells, plant protoplasts, plant pollen, liposomes, bacteria, fungi, yeast, sperm, or other suitable cells. The molecules are placed in close proximity to the cells, either in the interstitial space in tissue surrounding the cells or in a fluid medium containing the cells.
Description
- 1. Field of Invention
- The present invention generally relates to electro-cell manipulation. More particularly, the invention concerns an electroporation apparatus and method for generating and applying an electric field to a material while controlling temperature of the process using a Peltier device for effective molecular introduction into cells and minimize damage to cellular tissue.
- 2. Description of Related Art
- A cell has a natural resistance to the passage of molecules through its membranes into the cell cytoplasm. Scientists in the 1970s first discovered “electroporation,” where electrical fields are used to create pores in cells without causing permanent damage to them. Electroporation was further developed to aid in the insertion of various molecules into cell cytoplasm by temporarily creating pores in the cells through which the molecules pass into the cell.
- Electroporation has been used to implant materials into many different types of cells. Such cells, for example, include eggs, platelets, human cells, red blood cells, mammalian cells, plant protoplasts, plant pollen, liposomes, bacteria, fungi, yeast, and sperm. Furthermore, electroporation has been used to implant a variety of different materials, referred to herein as “implant materials,” “implant molecules,” “implant agents.” Namely, these materials have included DNA, genes, and various chemical agents.
- Electroporation has been used in both in vitro and in vivo procedures to introduce foreign material into living cells. With in vitro applications, a sample of live cells is first mixed with the implant agent and placed between electrodes such as parallel plates. Then, the electrodes apply an electrical field to the cell/implant mixture. Examples of systems that perform in vitro electroporation include the Electro Cell Manipulator ECM 600 product, and the Electro Square Porator T820, both made by the BTX Division of Genetronics, Inc. In San Diego, Calif.
- Known electroporation techniques for both in vitro and in vitro applications apply a brief high voltage pulse to electrodes positioned around the effectuating region. The electric field generated between the electrodes causes the cell membranes to temporarily become porous, whereupon molecules of the implant agent enter the cells. In known electroporation applications, this electric field comprises a single square wave pulse on the order of 1000 V/cm, of about 100 μs duration. Such a pulse may be generated, for example, in known applications of the Electro Square Porator T820, made by Genetronics, Inc.
- U.S. Pat. No. 5,442,272 teaches of a quick connect suction electrode assembly for electroporation that includes a temperature regulating element. However, there is no suggestion to integrate temperature control with an electroporation control for efficient and effective implant material processing.
- U.S. Pat. No. 5,185,071 teaches of a programmable electrophoresis apparatus using temperature controlling Peltier devices attached to the sides of a buffer chamber. This disclosure teaches only of electrophoresis applications.
- Although known methods of electroporation may be suitable for certain applications, the electric field may actually damage the electroporated cells in some cases. For example, an uncontrolled electric field and generated heat may damage the cells by creating permanent pores in the cell walls. In extreme cases, the electric field may completely destroy the cell caused by overheating during an electroporation event.
- Thus, existing electroporation systems may not be suitable for certain applications due to imprecise temperature control of implant agent materials and host cells during electroporation. Furthermore, many existing electroporation systems lack sufficient control over the parameters of the electric field pulses such as amplitude, duration, number of pulses during this process while simultaneously controlling the temperature of the implant materials.
- Broadly, the present invention concerns an electroporation method and apparatus for generating and applying an electric field while controlling temperature according to a user-specified control scheme. An exemplary electroporation temperature controlling receptacle device includes a cuvette, a holder and a Peltier device for controlling temperature, the receptacle is configured for either static or flow conditions. The invention also provides for integrated control of the electric field for electroporation to move the molecule into the cell while controlling temperature of the implant agent and host cellular material. The implant agent molecular material may be genes or drugs such as DNA, portions of DNA, chemical agents or any other molecule. The molecular material is placed in close proximity to the cells in a fluid medium containing the cells.
- Accordingly, one aspect of the present invention concerns a method of generating and applying an electric field according to a user-specified temperature control scheme integrated with an electroporation pulsing scheme for more efficient introduction of implant agents into cells and minimize damage to the cellular material.
- The present invention provides a number of distinct benefits. Generally, the invention is useful to introduce molecules of an implant agent into cells with significantly increased effectiveness. The implant agent, for example, may include drugs for treating cancer, kaposi's sarcoma, and a number of other diseases and conditions.
- In addition, by using electroporation to open cells for receipt of molecules of an implant agent, the invention increases the efficacy of the agent. Consequently, less of the implant agent is needed, thereby being more economical. The invention also provides a number of other benefits, as discussed in greater detail below.
- The nature, objects, and advantages of the invention will become more apparent to those skilled in the art after considering the following detailed description in connection with the accompanying drawings, wherein:
- FIGS. 1A, 1B,1C, 1D, 1E and 1F are diagrams illustrating various features of an electroporation cuvette and flow through chamber holders that include Peltier devices for temperature control for a contained or flow-through condition during the electroporation process.
- FIG. 2A and 2B show the electroporation and temperature control hardware and interconnections to the receptacle holders in perspective and block diagram form pursuant to the present invention;
- FIG. 3 is a diagram illustrating an electroporation waveform known in the art;
- FIG. 4 is a diagram of an exemplary hardware components and interconnections of an electroporation pulse controller and generator subsystem pursuant to one aspect of the present invention;
- FIG. 5 is a diagram of an exemplary article of manufacture, comprising a data storage medium, in accordance with one aspect of the present invention;
- FIG. 6 is a flowchart illustrating an exemplary sequence of method steps in accordance with one aspect of the present invention; and
- FIG. 7 is a drawing illustrative of an electroporation pulse, pursuant to the invention.
- FIGS.8-11 are drawings of illustrative electroporation pulsing schemes with temperature control, pursuant to the invention; and
- FIG. 12 is a flowchart illustrating an exemplary sequence of method steps in accordance with one example of the present invention.
- As mentioned above, one aspect of the present invention concerns an electroporation apparatus and method for processing implant agents into cells by generating and applying an electric field to these materials while controlling temperature during the processing with a user selected control scheme of temperature for efficient and effective introduction of these materials to minimize damage to cellular tissue. Precision temperature control of the processing is provided by an integrated Peltier device with the electroporation apparatus using processor control.
- Receptacle:
- FIG. 1A illustrates a first preferred exemplary embodiment of the invention showing in cross-section a
cuvette 5 which is a receptacle for both host cells and implant materials undergoing electroporation. FIG. 1B illustrates an alternate exemplary embodiment using a flow throughcuvette 5 a, which comprises a clear plastic rectangular housing defining anenclosure 9 having a round opening at the upper end. This is similarly taught in U.S. Pat. No. 5,676,646 - entitled “Flow Through Electroporation Apparatus,” which is incorporated by reference. Both of these receptacles can be in disposable-form. An example of the
cuvette 5 is BTX brand cuvette, model number 640 made by Genetronics, Inc. of San Diego, Calif. Thecuvette 5 is portable and can be insertable into acuvette holder 10. Thecuvette holder 10 is a platform, which supports thecuvette 5 for electroporation processing and electrically interfaces with electroporation andtemperature controller 100. - This opening is closed by a push-on
plastic cap 9. Thetubing segment 130 extends snugly through a hole in the middle of thecap 9 at one end of the chamber. Thetubing segment 132 extends through a hole in the lower end of theenclosure 2 which is sealed with afitting 6. Theenclosure 2 is preferably molded with a pair of embeddedelongated electrodes electrodes temperature control assembly 100. Theelectrodes receptacle 5 a, between the inlet and outlet to enable fluid to pass therebetween. The electrodes (7 and 8) and (40 and 42) may be of any suitable conductive material such as stainless steel or aluminum and may be gold plated. - Receptacle Holder:
- The holder10 (FIG. 1A) in exemplary form is an electrically insulated platform with terminals for connecting at least two
independent conductors 11, 13 for supplying the electrical energy for both the electroporation pulses and causing thePeltier devices 44 to transfer heat energy to or from the receptacle andholder assembly 20. Theholder device 10 is typically made of delrin or other nonconducting material with a screw clamping member for placement of acuvette holder 10. Theelectrodes electrodes holder 10, but can be integrated in a single unit if required. An example of such a cuvette holder without components for regulating temperature is a BTX brand Safety Stand model 630-B made by Genetronics, Inc. of San Diego, Calif. Such a holder can also include an electrical safety interlock feature incorporated into a hood covering member to prevent electrical shock to personnel when operated. - The
holder 10 preferably uses a plate-shapedelectrodes Peltier devices 44 incorporated therein that allows for rapid heating or cooling of host and implant materials in the cuvette. ThePeltier device 44 contained in theelectrodes temperature sensor 58 can be attached to theholder 10 for maintaining close proximity to the cuvette during processing to provide closed-loop processing temperature control in real-time. Thetemperature sensor 58 can be, for example an infrared temperature sensor that is attached to a hood member of theholder 10 such that when closed, accurate temperature measurement of the material undergoing electroporation is achieved. - Before electroporation begins, the receptacle receives cellular and implant materials for in vitro use, the materials are cells and implant agent materials placed in either form of the
cuvette - Flow-Through Receptacle:
- FIG. 1C illustrates another embodiment of the receptacle device in a flow-through
chamber 54 form. This receptacle device is taught in U.S. Pat. No. 5,676,646 entitled “Flow Through Electroporation Apparatus,”. except for the means for controlling temperature of the materials. Thechamber 54 receptacle device receives cellular and implant materials for in vitro use by withdrawing fluids from a reservoir or human for processing during transmission. The flow through receptacle andholder unit 20 comprises a rectangularouter housing 57 which encloses an elongated flow throughchamber 54. It includes a pair of uniformly spaced apart elongated electrodes in the form of a cylindricalconductive rod 55 concentrically mounted with acylindrical vessel 57 defining opposed parallel electrode surfaces. Preferably, therod 55 andvessel 57 are made of stainless steel and may be gold plated where desired. The ends of the electrodesurface forming rod 55 andvessel 57 are mounted inhollow blocks rings 63. The O-rings are seated within circular groves machines inside theblocks - The
blocks rod 55 andvessel 57. Theblocks Fittings 71 and 72 (FIG. 2A) are screwed into the threaded walls of the inlet and outlet ports at 65 and 67 forcoupling tubing segments 74 and 76 thereto. Thetubing segments 74 and 76 extend within thehousing 52 and are in turn connected to fitting 78 and 80 mounted on the front panel of the housing. Thetubing segments fittings - The
electric cables 136 and 138 (FIG. 2A) from the electroporation andtemperature subsystem 100 have plugs that are removably connected tojacks housing 52 of the flow through chamber unit. These jacks are in turn connected towires nut electrode assemblies 40 or 42 (FIG. 1C) as one electrode and to a clamp aroundvessel 57 as the other electrode of the flow throughchamber 54. Theelectrode nut assembly rod electrode 55 while theassembly 42 provides an electrical connection to thevessel electrode 57. ThePeltier devices 44 are mounted to the external ends of thenut electrode structures - FIG. 1D shows another embodiment of a flow through
chamber receptacle holder 101 that can be used with a peristaltic pump (not shown) with aninput receiving tube 110. This is taught in U.S. Pat. No. 5,676,646, except for components for controlling temperature of the materials undergoing electroporation. This flow through electroporation chamber receptacle includes asafety stand 116, having a generally U-shaped configuration with aslot 118 for receiving the disposable chamber formed between opposing sides, or thermally conductingpanels side panel 122 is provided with upper andlower slots tubes - FIG. 1E shows the chamber, within which, the materials undergoing electroporation pass through comprises a central generally rectangular bar-shaped
body member 128 having an elongated centrally disposed throughslot 130 formed therein as shown in FIG. 1D. Theslot 130 is enclosed on opposite sides of the bar-shapedbody member 128 by means of a pair of bar shapedelectrodes central body member 128 is preferably constructed of a nonconductive material whereas thebar electrodes tubes slot 130. The flow through chamber receptacle is assembled with theelectrodes Peltier devices 44, sealingly engaging opposite sides of thebar 128 enclosing theslot 130. The electrodes are preferably, sealingly bonded by suitable means to the opposite sides of the central bar member. The assembled chamber then slides into theopen slot 118 in thesafety stand 116 between a pair of opposingspring contacts conductive holders - FIG. 1F shows the electrical cables in a
top view backplate 152. A pair of conductive cables, 144 and 146, include leads 148 and 150 connected such as by soldering to therespective holders Spring contacts - Variations of the cuvette can be use of a concentric annular electrode structure wherein a center electrode would be at the center of the cuvette and an outer electrode would be on the surface of the cuvette. A variation of the
holder 10 would include an electrode that attaches through the top center and center of the cuvette with an outer electrode interfacing with the cuvette which would contain thePeltier device 44. At least one Peltier device must be incorporated with thecuvette corresponding holder 10. Preferably, theelectrodes - Electroporation and Temperature Subsystem:
- An electrical pulsing field is placed across the material between
electrodes holder assemblies 20. Theelectrode structures electrodes electrodes subsystem 100 to provide a pulsing electric field across the materials undergoing electroporation. Control of the electroporation pulsing scheme by an electric field which varies in both magnitude and duration improves transfection of gene material. The preferred electroporation pulsing scheme is taught in U.S. patent application Ser. No. 08/709,615, entitled “Electroporation User Configured Pulsing Scheme,” which is hereby incorporated by reference. - In addition to providing an electrical pulsing scheme that is user-programmable, the present invention provides temperature control of the material that is undergoing electroporation which naturally warms or cools the materials contained within the receptacle when electric fields are transmitted therethrough. The receptacle and
holder assembly 20 is equipped with aPeltier device 44 for the temperature control during the electroporation process. ThePeltier device 44 is electrically and thermally junctured at theelectrodes Peltier device 44 receives current from an external, feedback regulated power supply forming part of thesubsystem 100. ThePeltier device 44 controls temperature within <±0.1C. Controlling material temperature during the electrical pulsing electroporation treatment provides an improved material yield. - FIG. 2A shows an exemplary application of the apparatus that is used with a peristaltic pump (not shown), and injection pump (not shown), a flow through receptacle
chamber receptacle assembly 89 and the electroporation andtemperature control subsystem 100. This is similarly taught in U.S. Pat. No. 5,676,646 entitled “Flow Through Electroporation Apparatus,” except for the means for controlling material temperature. The apparatus includes a pair of electric cables for connecting thesubsystem 100 with the flow throughreceptacle assembly 89. - FIG. 2B illustrates a block diagram showing the components for controlling the pulsing field magnitude, field duration and temperature control of the
cuvette holder 10 with receptacle device. Beginning with temperature control, thePeltier device 44 forms part of the electrode structures for receiving electrical input fromtemperature control block 56. Upon receiving electrical current fromtemperature control 56, the Peltier device transfers heat from the adjacent material within the receptacle to its external surface within theassembly 20. A temperature sensor may be used to communicate with the material undergoing electroporation to provide feedback signals totemperature control 56.Temperature sensor 58, which can be an infrared type sensor, receives temperature readings from the material in the electroporationcuvette holder device 10 and sends corrective signals totemperature control block 56 which then responds with an appropriate electrical signal toPeltier device 44. -
Temperature control block 56 functions to send an output electric signal todevice 44 in response to temperature sensor input. The output oftemperature sensor 58 is fed into an amplifier. The amplifier, can be contained within the analog portion of thetemperature controller 56. Also, withintemperature controller 56 is a comparator which receives the amplified signal and which functions to compare the amplified signal with an operator-initial or a reference signal sent through a digital-to-analog converter to the comparator. When the temperature is above the reference, the output from the comparator forward biases a power transistor with ratings of less than 100 amps and 100 volts which is connected in series with thePeltier device 44, thereby allowing cooling of materials in the cuvette or flow through receptacle. Conversely, heating can occur by reversing directional current through thePeltier device 44 by having a symmetrical connected type circuit attached to the electrode structures. To provide information for the control board, an amplified signal fromtemperature sensor 58 is sent to an analog to a digital converter and is used for reporting. This signal could, however, also be used for control through the user's program.Temperature control 56 is regulated bycontrol board 60 that is digital-based. Thecontrol board 60 interfaces to the analog-basedcontrol 56 via analog/digital converter 62 and digital/analog converter 64 (FIG. 2B). -
Control board 60 functions to control temperature of the material undergoing electroporation. Thecontrol board 60 receives its program from acontroller 66 and, once the program is entered, the keyboard and the computer are no longer necessary. Programming can be in computer languages such as C or BASIC (registered trade mark) if a personnel computer is used for the controller or assembly language if a microprocessor is used for thecontroller 66. A user specified control of temperature is programmed in thecontroller 66. - The
controller 66 may comprise a computer, a digital or analog processing apparatus, programmable logic array, a hardwired logic circuit, an application specific integrated circuit (“ASIC”), or other suitable device. In an exemplary embodiment, thecontroller 66 may comprise a microprocessor accompanied by appropriate RAM and ROM modules, as desired. Thecontroller 66 is coupled to a user interface 50 for exchanging data with a user. In the illustrated example, the user may operate the user interface 50 to input a desired pulsing pattern and corresponding temperature profile to be applied to theelectrodes Peltier device 44. The voltage polarity controls direction of heat flux to or from the receptacle device and current output to thePeltier device 44 can be either, amplitude or pulse width modulated for precision heat flux control. - As an example, the user interface50 may include an alphanumeric keypad, touch screen, computer mouse, push-buttons and/or toggle switches, or another suitable component to receive input from a human user. The user interface 50 may also include a CRT screen, LED screen, LCD screen, liquid crystal display, printer, display panel, audio speaker, or another suitable component to convey data to a human user.
Controller 66 used for inputting and outputting signals to controlboard 60 may be any type of ASCII terminal having an RS-232 or RS-485 port. The control board which receives input from the computer and produces outputs, can include an 8052-AH-BASIC microprocessor (8 Kb BASIC ROM, a programmable pulse generator, built-in algorithm using EEPROMs and EPROMs) 8 Kb of RAM, 8 Kb of battery-backed RAM, battery-backed real-time clock and timer with 0.005 sec resolution, 8 Kb of ROM command extensions, 8 Kb of EEPROM, 24 bits of programmable digital input-output, and an RS/232 printer port with a programmable Baud rate. -
Control board 60 functions to receivecontroller 66 input and is driven by thepower supply 70.Power supply 70 is a switching type which can have the following typical outputs: 12 volts with up to 20 amp output to thePeltier device 44, the RS-232 or RS-485 port, the digital toanalog converters temperature control block 56.Power supply 70 also provides −12 volts, 0.25 amps for the RS-232 port and the temperature control block. Additionally,power supply 70 would typically supply 5 volts and one amp to thecontrol board 60 and thetemperature control 56. - Electroporation Pulsing Subsystem:
- FIG. 3 (PRIOR ART) shows a pulsing scheme for electroporation as known in the art. To generate such a pulse, Prior electroporation power supplies used electromechanical relay to provide consecutive e first and second pulses, see S. I. Sukharev et al., Biophys. J. Vol. 63, November 1992, pp. 1320-1327. More particularly, Sukharev uses an
electric field pulse 101. Thepulse scheme 101 includes (1) a first, narrow duration,high voltage pulse 102, (2) adelay 103 of Δt, during which no pulse is generated, then (3) a second, wide duration,low voltage pulse 104. Thefirst pulse 102 was intended to porate the membrane, whereas thesecond pulse 104 was intended to electrophorese DNA into the cell cytosol. Sukharev recognized that thedelay 103 should not be excessive. - Although the Sukharev system may provide satisfactory results in some applications, this system may not be completely adequate for certain other applications. Some users may find, for example, that Sukharev's electroporation does not effectively move enough molecules of the implant agent into the target cells. This results from an
excessive delay 103 between Sukharev's first 102 and second 104 pulses, as recognized by the present inventor. The pores of a cell, created by electroporation, stay open for a finite time, largely depending upon the cell's temperature. Thus, the effect of the first pulse may start to significantly decay (thereby closing the cell's pores) during the delay between the first and second pulses. IR some applications, this may be sufficient to completely nullify the first pulse's effect upon the cell by the time the second pulse occurs. As a result, the efficacy of Sukharev's electroporation may be insufficient in some cases. Moreover, lacking an effective first pulse, the second pulse of Sukharev's system may need to be increased to the point where it permanently destroys cells. - The delay described above is inherent to the Sukharev system due to the use of electromechanical relays. Sukharev uses independent pulse generators, whose outputs are selectively coupled to output electrodes by a relay. As known in the art, however, the switching of an electromechanical relay typically takes a significant amount of time, sometimes even 50-100 ms. Therefore, the efficacy of the implant agent achieved by Sukharev may be too low for some applications.
- Electroporation Power Supply:
- FIG. 4 shows the pulsing
electroporation power subsystem 200 which receives an input voltage, such as 110V or 220 VAC, from apower source 203. Preferably, thesubsystem 200 includes a comparable apparatus, which is disclosed in U.S. patent application Ser. No. 08/709,615 and entitled “Electroporation User Configured Pulsing Scheme.”. Thesubsystem 200 has anelectroporation power supply 202 anddriver control 204 which controls or changes voltage magnitude, switch on or off, invert voltage polarity or provide voltage pulsing from thepower supply 202 toelectrodes control board 60 control provide the desired voltage or current output. Apower supply 202 provides a reliable source of desired voltage levels for use by the electroporation power control 201. An example of such a source is available, for example, from Electro Square Porator T820, made by the BTX Division of Genetronics, Inc. Either independent from or associated withpower supply 70 is anelectroporation power supply 202 which produces sufficient voltage range, preferably up to 500 volts. Thedivider 204 converts the input voltage into multiple reference voltages. In the illustrated embodiment, reference voltages of 500 V (D.C.) reside on thedivider output lines 204 a-204 b. - These voltages are provided to
collectors 206 b-207 b of first and second respective transistors 206-207. The transistors 206-207 are selectively gated to apply their input voltages to step voltage nodes 208-209. The selective gating of the transistors 206-207 is performed by respective comparators 212-213, which triggergates 206 a-207 a of the transistors 206-207 when voltages at the step voltage nodes 208-209 dips below voltages established on step voltage input lines 216-217. For example, when thecomparator 212 determines that the voltage on thestep voltage node 208 is less than the voltage on thepreset input line 216, thecomparator 212 activates thegate 206 a of thetransistor 206, causing thetransistor 206 to couple the input voltage of thedivider 204 directly to thestep voltage node 208. Thus, thetransistors 206 maintain substantially constant voltages at the respective step voltage nodes 208-209 in accordance with the step voltage input lines 216-217. - Energy Reservoirs:
- The
subsystem 200 also includes energy reservoirs 220-221 coupled to respective step voltage nodes 208-209. Exemplary energy reservoirs 220-221 may comprise capacitors, such as 3200 μF, 500 V electrolytic capacitors. These capacitors are appropriate for maximum step voltages 208-209 of 500 V (D.C.). - Transformer:
- The
subsystem 200 also includes atransformer 224, which includes a primary winding 224 a and a secondary winding 224 b. Thetransformer 224 preferably is designed with low leakage inductance characteristics to provide a fast pulse rise time, i.e., several microseconds. Preferably, thetransformer 224 exhibits low inductance, on the order of a few μH. These features may be provided by winding thetransformer 224 with a single cable of twelve separate, twisted conductors of which six are connected in parallel for the primary, six are connected in series for the secondary. This provides a 1:6 step-up ratio. In addition, a separate low voltage D.C. bias winding around the core may be used to employ the full flux swing of the transformer's core. As an example, the transformer may utilize a core made of laminated iron. - The
transformer 224 may advantageously be constructed to saturate if the pulse length exceeds a maximum prescribed value, thereby protecting a patient from excessive electrical energy. Preferably, thetransformer 224 is capable of carrying 0.3 V-sec (3000 V×100 μsec) before saturation. Another advantage of thetransformer 224 is that its output is floating, and no substantial current will flow if the patient is connected to ground potential. The secondary winding 224 b is coupled to output connection nodes 230-231, which preferably connect to thecuvette holder device 10. - The load between the
electrodes cuvette holder 10 which may contain platelets, human cells, red blood cells, mammalian cells, plant protoplasts, plant pollen, liposomes, bacteria, fungi, yeast, sperm, or other cells. - To protect the
energy reservoir 220 andpower supply 202, adiode 236 may be placed between theenergy reservoir 220 and theconnection 230. Likewise, to protect theenergy reservoir 221 andpower supply 220, adiode 237 may be placed between the secondary winding 224 b and theconnection 230. - Switches:
- The
subsystem 200 also includes switches 226-227 to selectively enable current to flow through the primary andsecondary windings 224 a-224 b, respectively. In one exemplary construction, each switch 226-227 may comprise an insulated gate bipolar transistor (“IGBT”), such as a Fuji Electric brand IMBI400F-060 bmodel IGBT. - The
switch 226 and theenergy reservoir 221 are coupled in series, this series combination being attached in parallel with the primary winding 224 a. When voltage is applied to agate 226 a of theswitch 226, thecollectors 226 b andemitter 226 c are electrically connected. Thus, theenergy reservoir 221 is effectively placed in parallel with the primary winding 224 a. This allows current from the energy reservoir 121 to flow through the primary winding 224 a. - Similarly, the
switch 227 andenergy reservoir 220 are coupled in series, this series combination being attached in parallel with the secondary winding 224 b. When voltage is applied to agate 227 a of theswitch 227, thecollectors 227 b andemitter 227 c are electrically connected. Thus, theenergy reservoir 220 is effectively placed in parallel with the secondary winding 224 b. This allows current from theenergy reservoir 220 to flow through theelectrodes - Advantageously, none of the energy reservoirs220-221 or switches 226-227 grounds the
windings 224 a-224 b. Thewindings 224 a-224 b, therefore electrically float. As a result, no substantial current will flow through a patient or other load 234 that is connected to another earth or ground potential. - Electroporation Pulse Controller:
- Another component of this example of the
subsystem 200 is the power control 201, which manages operation of the switches 226-227. Broadly, thecontroller 66 114 (FIG. 2) regulates the on-times and off-times of the switches 226-227 in accordance a specified schedule, thereby generating a predetermined pulsing scheme at theelectrodes switch 227, the voltage of theenergy reservoir 220 is applied to theelectrodes switch 226, the voltage of theenergy reservoir 220 is applied to thetransformer 224, where it is multiplied by six and applied to the connections 230-231. The controller 66 (FIG. 2B) may also trigger both switches 226-227 to apply an additive voltage, comprising the sum of the step voltages 208-209, to theelectrode structures - Preferable Design Parameters:
- The electrical requirements can be derived from the field strength, which was determined efficacious from in vitro experiments with tumor cells and drugs, typically 1200-1300 V/cm, and a pulse length of about 100 μsec. The maximum voltage of the generator derives from the maximum cavity size used.
- As an example, the material resistivity is assumed to be as low as 100 Ohm×cm. With an electrode area of 3 cm×3 cm=9 cm2, the resistance is 22 Ohm. The internal impedance of the generator should be at least a
factor 10 lower than 22 Ohm so that no substantial drop in voltage occurs between charging and delivered voltage. With the maximum voltage of 3000 V and a load impedance of 22 Ohm, the switching requirements from a partial capacitor discharge to generate a square pulse are a very substantial 400 kW. - The desired maximum permeation pulse length is 100 μsec; this results in an energy per pulse of 40 J. For the collection and electrophoresis pulse parameters, a maximum voltage of 500 V and maximum pulse length of 200 msec may be used.
- The maximum load current is about 136 A, which translates into a primary current of 6·136=816 A, which the switch has to carry and turn on and off. The switches226-227 can preferably maintain continuous current 800 A for one msec. The maximum voltage is 600 V. Transient spikes are limited to a maximum of 550 V for a 10% safety margin. This required careful low inductance mechanical assembly to reduce transients and to be able to get as close as safely feasible to the maximum voltage limit of the IGBT.
- The load impedance of 22 Ohm is transformed to the primary: 22/6×6−0.61 Ohm. A total internal impedance of 0.055 Ohm was achieved on the primary side of the transformer, which translates to an equivalent impedance of 1.98 Ohm on the secondary. Such a low impedance can lead to excessive currents in case of an arc or short circuit and these would destroy the expensive switching IGBT. The IGBT can be configured to contain a current limiting feature, which turns the switch off within a few μsec in case of excessive load currents which might happen if an arc or a short circuit condition occurs. By inducing an arc in the secondary, we measured a benign shut down of the IGBT within 5 μsec, as soon as the current exceeds about 900 A in the primary, corresponding to 150 A in the secondary.
- The necessary capacitor size can be estimated from the maximum allowable voltage drop across the load of 5%. The charge conducted in the primary pulse is 100 μs×816 A−0.08 Cb. If this should be 5% of the capacitor bank, the bank needs to hold 20×0.08=1.6 Cb. At 500 V maximum, the required capacity is C=Q/V=1.6/500=0.0032 F or 3200 μF. The energy stored in these capacitors is 400 Joule.
- For the collection and electrophoresis pulse, a second capacitor discharge circuit delivers the longer pulse lengths (several 100 msec) and low voltage (500 V) without the pulse transformer. The low voltage circuit and the high voltage circuit are decoupled from each other by stacks of
diodes - In addition to the various hardware embodiments described above, a different aspect of the invention broadly concerns a method for generating a user-specified electric field pulsing pattern to achieve improved electroporation.
- Data Storage Media:
- This method may be implemented, for example, by operating the
controller 66 to execute a sequence of machine-readable instructions. These instructions may reside in various types of data storage media. In this respect, one aspect of the present invention concerns an article of manufacture, comprising a data storage medium tangibly embodying a program of machine-readable instructions executable by a digital data processor to perform method steps to generate a user-specified electric field pulsing pattern to achieve improved electroporation. - This data storage medium may comprise, for example, RAM contained within the
controller 66. Alternatively, the instructions may be contained in another data storage medium, such as a magnetic data storage diskette (FIG. 5). Whether contained in thecontroller 66 or elsewhere, the instructions may instead be stored on another type of data storage medium such as DASD storage (e.g., a conventional “hard drive” or a RAID array), magnetic tape, electronic read-only memory (e.g., ROM), optical storage device (e.g., WORM), paper “punch” cards, or other data storage media. - Operational Steps:
- As mentioned above, one aspect of the invention broadly concerns a method for generating a user-specified electric field pulsing pattern to achieve improved electroporation. FIG. 6 shows a sequence of method steps400 to illustrate one example of this aspect of the present invention. For ease of explanation, but without any limitation intended thereby, the sequence of FIG. 6 is described in the context of the
subsystem 200 described above. - After the
steps 400 are initiated intask 402, thecontroller 66 intask 404 receives user input specifying an output pulse pattern of one or more output pulses. As an example, this user input may be received from the user interface 50. As an alternative, the user input may be received from another electronic device, or even a prestored record. - Preferably, the user input specifies a duration for each pulse and also specifying either a “high” output voltage or a “low” output voltage. Next, for each pulse of low predetermined voltage, the pulse generator in
task 404 generates the “low” predetermined voltage at theoutput terminals controller 66 may generate a low voltage pulse by gating theswitch 227, thereby permitting theenergy reservoir 220 to discharge through theelectrodes - Also, in
task 404, high voltage pulses are generated at the secondary winding terminals by concurrently applying another voltage to the primary winding terminals of the transformer for the specified duration. More particularly, the high voltage pulse involves generating the voltage as discussed above, while concurrently triggering theswitch 226 to permit theenergy reservoir 221 to discharge through the primary winding 224. As the voltage of thereservoir 221 is multiplied by thetransformer 224, a high voltage is created at the electrodes 230-231. This voltage is the additive sum of the voltages stored in the energy reservoirs 220-221. Alternatively, a lesser “high” voltage output may be created solely by triggering theswitch 226, without involving theswitch 227. - One or more of the above-mentioned pulses are therefore generated in
task 404 to produce the user-specified pulse pattern. After the user-specified pulsing pattern is created completed intask 404, the routine 400 ends intask 406. - Operation With Exemplary Pulsing Pattern:
- As mentioned above, the
pulse subsystem 200 provides a user-specified pulse pattern comprising one or more pulses of “high” and/or “low” output voltage. - Other exemplary pulse shapes, which may be used alone or in combination to constitute the user-specified pulsing scheme is taught in the U.S. patent application Ser. No. 08/709,615, as discussed above. FIGS.8-11 illustrate various exemplary pulse shapes, which may be used alone or in combination to constitute the user-specified pulsing scheme with associated temperature profile in real-time for processing of materials. The time scale is not necessarily linear as shown since the pulsing event occurs temporally in microseconds and cooling and heating of materials is an extrinsic factor of the apparatus used depending upon the receptacle device's volume for containing the materials and thermal design for effectuating heat transfer into or out of the receptacle device.
- Although each of the pulsing patterns of FIGS.8-11 may provide distinct advantages for different applications, the following description highlights the features and operation of a pattern 700 (FIG. 9) to illustrate the operation of the invention, both in the electroporation pulse scheme and temperature control in real-time. The polarity and current, which can be pulse width modulated, through the
Peltier device 44 directly correlates with temperature in the receptacle device. In the cooling phase of the materials undergoing electroporation, temperatures are typically around four degrees centigrade at the lower extreme and can be warmed to around 40 degrees centigrade. Desired material temperatures associated with electroporation pulsing in real time of particular cells and implant agents is functionally related to the type of cells and implant materials used and the desired outcome of the processing. Such control can be user specified and stored in a programmable form on a data storage media such as that shown in FIG. 5 and be implemented using the electroporation andtemperature controller 100. - The
pattern 700 comprises a “stepped pattern,” in that it provides first, second, and third voltage levels 702-704. One, two, or all of these voltages may be the same, if desired. The pulses have first, second, and third durations 706-708. In the present example, the first andthird voltages second voltage 707 provides 3000 V (D.C.). In an alternative embodiment, the user may specify a desired magnitude of electric field to be applied by thetransformer 224, and a measurement of the gap between theelectrodes controller 66 may compute the appropriate voltage for thetransformer 224 to generate in order to apply the desired electric field, for example by multiplying the electric field by the gap. In one embodiment, the gap measurement may be input by the user manually. Alternatively, the gap may be mechanically measured and electronically fed to thecontroller 66 by automated means such as shown in U.S. Pat. No. 5,439,440, which is hereby incorporated by reference in its entirety. - The efficiency of the implant agents to cells during electroporation processing is significantly dependent on the duration of cellular membrane permeabilization which has been discovered to be directly dependent on the temperature prior to, during and after pulsing application. Cellular permeability is modifiable by temperature changes. By raising the temperature, the permeability of the cellular wall is lowered. The lowering the ambient material temperature causes the permeability of the cellular material to increase.
- During initial processing, temperature should be lowered to around ice cooled temperatures, e.g., 4 degrees centigrade. After pulsing, usually several minutes, the temperature of the materials should be raised to around 40 degrees centigrade to seal and anneal the cellular membrane. However. some cellular materials are very sensitive to temperature and cannot survive extreme temperature changes. In such cases, cellular manipulations need to be carried out at the optimal cell survival conditions.
- The corresponding temperature profile in real time would exist and be controlled by the
Peltier device 44 in the materials undergoing electroporation. The causal relationship of temperature effects when materials undergo electroporation has been studied and demonstrated that cellular membrane alterations do occur under varying temperature and electrical fields. In particular, this is taught in an article entitled “Studies on Electroporation of Thermally and Chemically Treated Human Erythrocytes,” by Nanda et al. in Bioelectrochemistry and Bioenergetics, 34 (1994) 129-134. Temperature is a significant factor during electroporation processing of cells such as red blood cells with implant agents. When temperature increases during electroporation processing, effectiveness is significantly reduced. For example when using red blood cells, Increase in the temperature during electroporation from four to forty-three degrees Centigrade reduces electroporation efficiency by approximately 50%. Post pulse incubation of red blood cells at higher temperatures further reduces the electroporation effectiveness. - FIG. 12 describes an
illustrative sequence 2000 involved in generating and applying thestep pattern 700, and the effects caused by application of thepattern 700 with corresponding control of temperature. After the sequence begins intask 1002, the user interface 50 receives user input intask 1004. In the illustrated embodiment, the user input includes the user's specification of a desired electroporation pulsing pattern, including a duration and voltage level for each pattern portion and the corresponding control of temperature. - Concurrently with
task 1004, thepower supply 202 generates the reference voltages at the output nodes 208-209. In the present example, the reference voltages 208-209 of 500 V (D.C.) are used. Generation of the reference voltages intask 1008 charges the energy reservoirs intask 1008. - After
task 1008, an operator intask 1010 inserts molecules of an implant agent to the receptacle device for processing. The implant agent may comprise one or more types of DNA, genes, and/or various chemical agents. -
Step 1010 places the implant agent between the interstices of the cells at the process site. Next, intask 1012 thePeltier device 44 cools the materials in the receptacle device to around ice temperatures for most processing applications. However, warming of materials undergoing processing can be implemented. - After
task 1012, thecontroller 66 intask 1014 gates theswitch 227, discharging theenergy reservoir 220, thereby applying the “low” voltage to theelectrodes - Accordingly, the “low” voltage of the
energy reservoir 220 achieves this purpose, while still avoiding damage to the cells in the sample and saving electrical energy. - FIG. 9 illustrates
task 1014 as thevoltage pulse 702. As shown, this pulse preferably comprises a square wave having aduration 706 of about 10-200 msec and a voltage of about 500 V (D.C.). Depending upon the application, however, different parameters may be substituted to define thepulse 702. A corresponding cooling period occurs to allow greater permeability of cellular materials undergoing processing. - After
task 1014, thecontroller 66 intask 1016 gates theswitch 226 on (while continuing to gate the switch 227). This creates a “high” voltage upon theelectrodes voltage pulse 703. As illustrated, this pulse preferably comprises a square wave having aduration 707 of about 100 μsec and an electric field magnitude of about 1200 V/cm. Depending upon the application, however, different parameters may be substituted to define thepulse 702. The temperature is maintained at the cool state during processing to maintain high permeability of a cellular membrane undergoing processing. - Advantageously, the
subsystem 200 automatically limits damage to cells of the tissue sample during this step. In particular, when the voltage from the primary winding 224 a saturates the secondary winding 224 b, the voltage presented by the secondary winding 224 b begins to decay, in accordance with known principles of transformer operation. Thus, even if the voltage applied to the primary winding 224 a is applied for an excessive length of time, the secondary winding 224 b automatically limits the tissue sample's exposure to this high voltage pulse. - Next, in
task 1018 thecontroller 66 ceases gating of theswitch 226 while continuing to gate theswitch 227. This step permits the molecules of the implant agent to transit the cells' permeable membranes, and enter the cells' cytoplasm. - FIG. 10 illustrates this step as the
voltage pulse 704. As illustrated, this pulse preferably comprises a square wave having aduration 708 of about 1-200 msec and a voltage of about 500 V (D.C.). Depending upon the application, however, different parameters may be substituted to define thepulse 704. - After
task 1018, thecontroller 66 releases gating of theswitch 227, ending thepulse 700. Then, thePeltier device 44 either warms or cools the material in the receptacle device intask 1022, and thesequence 2000 ends intask 1024. This step normally takes on the order of several minutes where it is either desirable to leave the cellular membrane open (keeping material cool) or sealing or annealing the cellular membrane (keeping the material warm). - Other uses of the invention provided herein include all electroporation mediated processes such as electrofusion, electroinsertion, electrochemotherapy, electrogene therapy and electrostimulation. While the presently preferred embodiments of the invention have been disclosed, it will be apparent to those skilled in the art that various changes and modifications can be made herein without departing from the scope of the invention as defined by the appended claims.
Claims (38)
1. An electroporation apparatus, the apparatus comprising:
receptacle means for providing a) an interface to a voltage of specified output pulsing, and b) temperature control of materials undergoing electroporation disposed within;
at least two spaced apart electrodes, at least one of the electrodes contains a Peltier device;
at least one opening to provide transfer of the materials;
a source of energy for energizing the at least two electrodes; and
a controller to receive user specification of an integrated output electroporation pulsing event with a corresponding temperature profile superimposed therewith, the controller outputs gating signals to the source of energy to generate the specified output pulsing and required polarity and magnitude to the Peltier device at the at least two electrodes, whereby the at least two electrodes enable temperature control and electroporation.
2. The apparatus of claim 1 , the controller including a microprocessor and the user specification of the electroporation pulsing event and required temperature of the materials undergoing electroporation by superposition of the gating signals to power supplies for electroporation and temperature control.
3. The apparatus of claim 1 , further comprising a user interface coupled to the controller for inputting the temperature profile.
4. The apparatus of claim 1 , the electrodes comprising plate electrodes.
5. The apparatus of claim 1 , further comprising:
a gap sensor to sense a distance between the electrodes and provide a representative electronic gap distance output signal.
6. The apparatus of claim 1 , wherein the controller and the energy source for generating the user specified electroporation pulse shape comprising:
a first power supply to provide a first output voltage;
a second power supply to provide a second output voltage, the first and second power supplies are separate sources of electrical energy;
a transformer having electromagnetically coupled primary and secondary windings, the secondary winding being interposed between a pair of terminals;
a first switch coupled to the first power supply and the primary winding and being responsive to a first gating signal to apply the first output voltage from the first power supply to the primary winding;
a second switch coupled to the second power supply and the secondary winding and responsive to a second gating signal to apply the second output voltage from the second power supply to the secondary winding; and
a controller to receive user specification of an output pulse shape and provide the first and second gating signals to generate the specified output pulse shape at the terminals.
7. The apparatus of claim 5 , the controller further being programmed to perform steps comprising:
receiving an input specifying a desired electric field;
receiving an input specifying an electrode gap distance; and
calculating a first voltage to provide the specified electric field across the specified electrode gap distance.
8. The apparatus of claim 6 , further comprising:
a pair of electrodes electrically connected to predetermined contacts of the transformer;
a gap sensor to sense an electrode gap distance between the electrodes and provide a representative electrode gap distance output signal;
wherein the controller is further programmed to perform steps comprising:
receiving an input of a desired electric field;
receiving the electrode gap distance output signal; and
computing the first voltage to provide the input desired electric field across the electrodes.
9. The apparatus of claim 1 , wherein the controller and the energy source for generating the user specified temperature state during the electroporation pulsing event includes means for controlling polarity of electrical energy at the at least two electrodes from the controller that controls heat flow using the Peltier device.
10. The apparatus of claim 6 , wherein the controller and the energy source includes means for controlling polarity and power magnitude to the at least two electrodes thereby controlling direction of heat transfer from the Peltier device, the controller includes a temperature sensor for closed loop control of the Peltier device.
11. The apparatus of claim 1 , wherein the receptacle means comprises a cuvette with at least one integral electrode contact surface attached to external surfaces of the cuvette, the at least one cuvette electrode is configured to slidably interface with and maintain positioning in a holder device, the holder device includes the at least one Peltier device in a complementary electrode structure that interfaces with at least one of the electrodes forming part of the cuvette, the holder has terminals with means for connection to the controller.
12. The apparatus of claim 11 , wherein the cuvette is a non-flow type containing device.
13. The apparatus of claim 11 , wherein the cuvette is a flow through containing device.
14. A receptacle device and complementary holder device for electroporation in kit form, the kit comprising:
the receptacle device has at least two electrode structures for providing an interface to a specified output voltage pulsation waveform and heat transfer control for materials contained within the device;
at least one Peltier device forming a junction with at least one of the electrode structures; and
means for providing positional stability for the receptacle device and connecting the at least two electrode structures to a connectable external controller.
15. The kit of claim 14 , the electrodes comprising plate electrodes.
16. The kit of claim 14 , further comprising:
a gap sensor to sense a distance between the electrodes and provide a representative electronic gap distance output signal.
17. The kit of claim 14 , wherein the receptacle device provides for liquid flow through the receptacle device that includes:
the receptacle device including an elongated flow through chamber having an inlet and an outlet at opposite ends thereof; and
a pair of elongated spaced apart parallel internal electrodes disposed in and extending along opposite sides of the chamber between the inlet and the outlet for fluid to flow between.
18. The kit of claim 17 , wherein the receptacle device comprises a generally elongated nonconductive bar member having a rectangular cross section and an elongated through slot intermediate the ends thereof,
the electrodes are elongated flat conductive members sealingly applied to opposite sides of the bar member closing the slot and defining the elongated flow through chamber.
19. The kit of claim 18 , wherein the inlet and the outlet are formed in one of the electrodes and communicate with opposite ends of the slot.
20. The kit of claim 19 , wherein the receptacle device further comprises a generally U-shaped housing formed of a non-conducting material and having a pair of parallel side walls with an opening therebetween for removably receiving the flow through chamber.
21. The kit of claim 20 , wherein the U-shaped housing includes slots in one side thereof for accommodating tubing connected to the inlet and the outlet.
22. The kit of claim 17 , wherein the electrodes extend substantially the full length of the flow through chamber.
23. The kit of claim 22 , wherein the flow through chamber comprises an elongated nonconductive tubular member;
a header on one end of the tubular member defining one of the inlet and the outlet; and
a pair of elongated conductive bars extending along opposite sides of the tubular member defining the electrodes.
24. The kit of claim 17 , wherein the flow through chamber comprises an elongated conductive tubular member defining one of the electrodes, and a pair of headers on the ends of the tubular member defining the inlet and the outlet; and
a conductive rod extending coaxially of the tubular member defining the other of the conductors.
25. The kit of claim 17 , wherein the flow through chamber substantially rectangular in cross section.
26. The kit of claim 25 , wherein the flow through chamber comprises an elongated nonconductive tubular member;
a header on one end of the tubular member defining one the inlet and the outlet; and
a pair of elongated conductive bars extending along opposite sides of the tubular member defining the electrodes.
27. A method for regulating temperature of an electroporation pulse apparatus that includes a receptacle means for containing and controlling temperature of a material contained within, the receptacle means has an electrode structure that includes a Peltier device;
receiving user input specifying an output pulse pattern of at least one output pulse for effectuating electroporation of the material, the user input specifying a duration for each pulse wherein the pulse pattern defines an event;
receiving a second user input specifying an output pulse pattern for controlling temperature of the material during the event.
28. The method of claim 27 , the material comprising cells removed from a living being.
29. A method of electroporation using a cuvette holder comprising:
positioning a pair of electrodes containing a Peltier device relative to a region of cells;
applying at least one voltage pulse to the electrodes of specified polarity and
delivering a predetermined implant agent to the region of cells at a specified temperature;
moving molecules of the implant agent toward the cells by applying at least one pulse at a
second voltage to the electrodes for a second predetermined time;
creating pores in a plurality of the cells; and
moving molecules of the implant agent into a plurality of the pores while controlling temperature.
30. The method of claim 29 , the second predetermined magnitude of voltage providing a resultant electric field at the electrodes in the range of 300-3000 V/cm.
31. The method of claim 29 , further comprising the steps of computing the second predetermined magnitude of voltage by multiplying a desired electric field by measurement of a gap existing between the electrodes.
32. An article of manufacture comprising a data storage medium tangibly embodying a program of machine-readable instructions executable by a digital processing apparatus to perform method steps for generating an electroporation pulse pattern in an electroporation pulse apparatus that includes a electrode structure containing Peltier material, the method comprising:
receiving user input specifying an output pulse pattern of one or more output pulses, the user input specifying a of an integrated output electroporation pulsing event with a corresponding temperature profile; and
providing gating signals to generate the specified output pulsing at the electrode structure.
33. The article of manufacture of claim 32 wherein the data storage medium tangibly embodying a program of machine-readable instructions executable by a digital processing apparatus to perform method steps for electroporation and temperature control, the method further comprising:
(a) applying an electric field of a first predetermined magnitude to a region of cells for a first predetermined duration;
(b) increasing the electric field to a second predetermined magnitude greater than the first predetermined magnitude; and
(c) reducing the electric field to a third predetermined magnitude less than the second predetermined magnitude.
34. An apparatus for programmable control of an electroporation device, comprising:
a receptacle for containing a material undergoing electroporation, the receptacle includes at least two electrodes for effectuating the electroporation process of the material when disposed in the receptacle;
programmable means for controlling a excitation of a pulsing scheme at the electrodes for controlling the magnitude and polarity of the electric field of a Peltier means connected to the electrodes for regulating the temperature of the material within the receptacle and the electroporation process.
35. The apparatus as recited in claim 34 , wherein the programmable controlling means comprises:
a control board electrically connected to each electrode for controlling magnitude, polarity and duration of electrical energy supplied to each the electrode.
36. The apparatus as recited in claim 34 , wherein the Peltier means comprises:
within each electrode having an internal and external surface, the internal surface configured for containing the material whereby the internal surface is a thermally conductive sheet;
a Peltier device having an internal and external surface, whereby the internal surface of the cell is attached to the external surface of each the plate; and
a control board electrically connected to each cell for inputting electrical input to the cell which, in response to the electrical input, the cell transfers heat to and from the material.
37. The apparatus as recited in claim 34 wherein the control board is a microprocessor and memory-based controller with programmable pulse generator.
38. An apparatus for programmable control of an electroporation process comprising:
means for containing a material undergoing electroporation;
programmable means for controlling a magnitude of an electric field acting upon the material;
a controllable Peltier device for controlling heat flow to the material; and
control means for controlling the programmable means, the Peltier device, independent of one another.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/957,891 US20020068338A1 (en) | 1998-10-21 | 2001-09-20 | Electroporation apparatus for control of temperature during the process |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/176,136 US6150148A (en) | 1998-10-21 | 1998-10-21 | Electroporation apparatus for control of temperature during the process |
US70216600A | 2000-10-30 | 2000-10-30 | |
US09/957,891 US20020068338A1 (en) | 1998-10-21 | 2001-09-20 | Electroporation apparatus for control of temperature during the process |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US70216600A Continuation | 1998-10-21 | 2000-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020068338A1 true US20020068338A1 (en) | 2002-06-06 |
Family
ID=22643130
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/176,136 Expired - Fee Related US6150148A (en) | 1998-10-21 | 1998-10-21 | Electroporation apparatus for control of temperature during the process |
US09/957,891 Abandoned US20020068338A1 (en) | 1998-10-21 | 2001-09-20 | Electroporation apparatus for control of temperature during the process |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/176,136 Expired - Fee Related US6150148A (en) | 1998-10-21 | 1998-10-21 | Electroporation apparatus for control of temperature during the process |
Country Status (8)
Country | Link |
---|---|
US (2) | US6150148A (en) |
EP (1) | EP1121416B1 (en) |
CN (1) | CN1324398A (en) |
AT (1) | ATE242315T1 (en) |
AU (1) | AU6266699A (en) |
CA (1) | CA2344325A1 (en) |
DE (1) | DE69908631T2 (en) |
WO (1) | WO2000023563A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080934A2 (en) * | 2004-04-19 | 2006-08-03 | Invitrogen Corporation | Electroporation apparatus and methods |
EP2254997A1 (en) * | 2008-02-20 | 2010-12-01 | Bio-Rad Laboratories, Inc. | Electroporation cuvette with spatially variable electric field |
US20110238051A1 (en) * | 2010-01-25 | 2011-09-29 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associated devices, systems and methods |
US8676338B2 (en) | 2010-07-20 | 2014-03-18 | Zeltiq Aesthetics, Inc. | Combined modality treatment systems, methods and apparatus for body contouring applications |
US8702774B2 (en) | 2009-04-30 | 2014-04-22 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US9375345B2 (en) | 2006-09-26 | 2016-06-28 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US9408745B2 (en) | 2007-08-21 | 2016-08-09 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
US9545523B2 (en) | 2013-03-14 | 2017-01-17 | Zeltiq Aesthetics, Inc. | Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue |
USD777338S1 (en) | 2014-03-20 | 2017-01-24 | Zeltiq Aesthetics, Inc. | Cryotherapy applicator for cooling tissue |
US9655770B2 (en) | 2007-07-13 | 2017-05-23 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
WO2017117251A1 (en) * | 2015-12-28 | 2017-07-06 | Inovio Pharmaceuticals, Inc. | Electroporation device with improved signal generator |
US9737434B2 (en) | 2008-12-17 | 2017-08-22 | Zeltiq Aestehtics, Inc. | Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells |
US9844460B2 (en) | 2013-03-14 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same |
US9861421B2 (en) | 2014-01-31 | 2018-01-09 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US10383787B2 (en) | 2007-05-18 | 2019-08-20 | Zeltiq Aesthetics, Inc. | Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue |
US10524956B2 (en) | 2016-01-07 | 2020-01-07 | Zeltiq Aesthetics, Inc. | Temperature-dependent adhesion between applicator and skin during cooling of tissue |
US10555831B2 (en) | 2016-05-10 | 2020-02-11 | Zeltiq Aesthetics, Inc. | Hydrogel substances and methods of cryotherapy |
US10568759B2 (en) | 2014-08-19 | 2020-02-25 | Zeltiq Aesthetics, Inc. | Treatment systems, small volume applicators, and methods for treating submental tissue |
US10675176B1 (en) | 2014-03-19 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Treatment systems, devices, and methods for cooling targeted tissue |
US10682297B2 (en) | 2016-05-10 | 2020-06-16 | Zeltiq Aesthetics, Inc. | Liposomes, emulsions, and methods for cryotherapy |
US10731121B2 (en) | 2016-06-30 | 2020-08-04 | Zymergen Inc. | Apparatuses and methods for electroporation |
US10765552B2 (en) | 2016-02-18 | 2020-09-08 | Zeltiq Aesthetics, Inc. | Cooling cup applicators with contoured heads and liner assemblies |
US10935174B2 (en) | 2014-08-19 | 2021-03-02 | Zeltiq Aesthetics, Inc. | Stress relief couplings for cryotherapy apparatuses |
US10952891B1 (en) | 2014-05-13 | 2021-03-23 | Zeltiq Aesthetics, Inc. | Treatment systems with adjustable gap applicators and methods for cooling tissue |
US11076879B2 (en) | 2017-04-26 | 2021-08-03 | Zeltiq Aesthetics, Inc. | Shallow surface cryotherapy applicators and related technology |
US11154418B2 (en) | 2015-10-19 | 2021-10-26 | Zeltiq Aesthetics, Inc. | Vascular treatment systems, cooling devices, and methods for cooling vascular structures |
EP4001396A1 (en) * | 2020-11-17 | 2022-05-25 | Bühler AG | Device for treating cells in a bypass |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
US11395760B2 (en) | 2006-09-26 | 2022-07-26 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US11446175B2 (en) | 2018-07-31 | 2022-09-20 | Zeltiq Aesthetics, Inc. | Methods, devices, and systems for improving skin characteristics |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2395492A1 (en) * | 1999-12-22 | 2001-07-05 | Diana Wang | Method and apparatus for targeting localised electroporation |
DE10031179A1 (en) * | 2000-06-27 | 2002-01-31 | Amaxa Gmbh | Introducing active molecules into the nucleus of eukaryotic cells, useful for transfection and gene therapy, by applying controlled electrical pulse |
US7101703B2 (en) * | 2001-03-09 | 2006-09-05 | Cornell Research Foundation, Inc. | Electrofusion microelectrode |
DE10119901A1 (en) * | 2001-04-23 | 2002-10-24 | Amaxa Gmbh | Apparatus for electrophoretic transfer of biologically active molecules into cells comprises capacitors connected to high voltage sources, which discharge via power transistor into cuvette holding sample |
US6994706B2 (en) | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
US20030129716A1 (en) * | 2001-12-06 | 2003-07-10 | Bio-Rad Laboratories, Inc. | Automatic electroporation optimization system |
US6713292B2 (en) * | 2001-12-06 | 2004-03-30 | Bio-Rad Laboratories, Inc. | Electroporation cuvette insert for facilitating membrane-based fusion |
US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US6699712B2 (en) * | 2002-03-20 | 2004-03-02 | Bio-Rad Laboratories, Inc. | Electroporation chamber |
JP4753119B2 (en) * | 2003-03-14 | 2011-08-24 | セレクティス ソシエテ アノニム | Large volume in vitro electroporation method |
US6969604B1 (en) | 2003-06-20 | 2005-11-29 | Yakovenko Sergey A | Electroporation chamber |
US20050277183A1 (en) * | 2004-05-18 | 2005-12-15 | Ronald Lee | Electroporation cuvette |
ES2465467T3 (en) * | 2004-06-14 | 2014-06-05 | Lonza Cologne Ag | Procedure and circuit layout for the treatment of biological material |
US7915044B2 (en) * | 2005-12-22 | 2011-03-29 | Cornell Research Foundation, Inc. | Electrofusion microelectrode and methods of using it to manipulate cells and/or cellular components |
US7687267B2 (en) * | 2006-09-30 | 2010-03-30 | Rational Biotechnology Inc. | High-throughput cell transfection device and methods of using thereof |
CN105457157B (en) | 2006-10-17 | 2020-04-14 | 因诺维奥制药公司 | Electroporation device and method for mammalian cell electroporation using the same |
ES2534579T3 (en) * | 2007-02-23 | 2015-04-24 | Lonza Cologne Gmbh | Device and procedure to stabilize the flow through a chamber |
WO2009123564A1 (en) * | 2008-04-03 | 2009-10-08 | Nanyang Polytechnic | Apparatus for electroporation with cooling system |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
ES2657700T3 (en) | 2009-01-20 | 2018-03-06 | Lonza Cologne Gmbh | Procedure and device for the electrical treatment of several containers |
EP2208778A1 (en) | 2009-01-20 | 2010-07-21 | Lonza Cologne AG | Method and device for electric processing of reaction areas |
US8632534B2 (en) * | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
WO2011050009A1 (en) * | 2009-10-19 | 2011-04-28 | Rational Biotechnology Inc. | Method, device and apparatus for inducing self-adjusting cell electroporation |
EP2399984B1 (en) | 2010-06-22 | 2013-03-20 | Lonza Cologne GmbH | Method and electrode assembly for treating adherent cells |
CA2809360A1 (en) | 2010-09-27 | 2012-04-05 | China Agricultural University | Combined antigen and dna vaccine for preventing and treating autoimmune diseases |
EP2627274B1 (en) | 2010-10-13 | 2022-12-14 | AngioDynamics, Inc. | System for electrically ablating tissue of a patient |
WO2012088149A2 (en) * | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
CN103239734B (en) | 2012-02-10 | 2016-02-24 | 北京艾棣维欣生物技术有限公司 | For preventing and/or treating the vaccine of respiratory syncytial virus infection |
JP6523174B2 (en) | 2012-12-13 | 2019-05-29 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | WT1 vaccine |
US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
EP3003342B1 (en) | 2013-05-30 | 2022-01-26 | Duke University | Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates |
KR20160066033A (en) | 2013-10-07 | 2016-06-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Vaccines with interleukin-33 as an adjuvant |
US10370664B2 (en) | 2013-11-07 | 2019-08-06 | University Of Southern California | Use of IKK epsilon inhibitors to activate NFAT and T cell response |
EP3068427A1 (en) | 2013-11-14 | 2016-09-21 | The Trustees Of The University Of Pennsylvania | Hiv-1 env dna vaccine plus protein boost |
AU2014354797C1 (en) | 2013-11-29 | 2018-02-01 | Inovio Pharmaceuticals, Inc. | MERS-CoV vaccine |
EP3092004A4 (en) | 2014-01-06 | 2017-02-22 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
DK3260163T3 (en) | 2014-05-02 | 2019-09-02 | Lonza Cologne Gmbh | Large volume transfection device and method |
JP6594901B2 (en) | 2014-05-12 | 2019-10-23 | バージニア テック インテレクチュアル プロパティース インコーポレイテッド | Selective modulation of intracellular effects of cells using pulsed electric fields |
EP3200831A4 (en) | 2014-10-01 | 2018-02-21 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
KR20170106453A (en) | 2015-01-29 | 2017-09-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Use of gating inhibitors and vaccines for their combination and immunotherapy |
WO2016154530A1 (en) | 2015-03-26 | 2016-09-29 | Duke University | Targeted therapeutic agents comprising multivalent protein-biopolymer fusions |
AU2016301391B2 (en) | 2015-08-04 | 2022-07-28 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
EP3393500B1 (en) | 2015-12-21 | 2021-10-13 | Duke University | Polymer conjugates having reduced antigenicity |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
US11246924B2 (en) | 2016-04-01 | 2022-02-15 | Duke University | Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform |
WO2017190147A1 (en) | 2016-04-29 | 2017-11-02 | Inovio Pharmaceuticals, Inc. | The in vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
RU2019110848A (en) | 2016-09-14 | 2020-10-15 | Дьюк Юниверсити | NANOPARTICLES BASED ON TRIBLOC POLYPEPTIDES FOR DELIVERY OF HYDROPHILIC MEDICINES |
EP3515928A4 (en) | 2016-09-23 | 2020-04-01 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US10376495B2 (en) | 2016-11-23 | 2019-08-13 | University Of South Florida | Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF) |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
US10813935B2 (en) | 2017-02-23 | 2020-10-27 | Transgenex Nanobiotech, Inc. | Methods and compositions for treating drug resistance in cancer |
US11318155B2 (en) | 2017-02-24 | 2022-05-03 | University Of South Florida | Hsp90 activator Aha1 drives production of pathological tau aggregates |
WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
ES2913457T3 (en) | 2017-06-30 | 2022-06-02 | Inscripta Inc | Automated Cell Processing Methods, Modules, Instruments and Systems |
WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
US10738327B2 (en) | 2017-08-28 | 2020-08-11 | Inscripta, Inc. | Electroporation cuvettes for automation |
CN111372650A (en) | 2017-09-30 | 2020-07-03 | 因思科瑞普特公司 | Flow-through electroporation apparatus |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
WO2019190874A1 (en) | 2018-03-29 | 2019-10-03 | Inscripta, Inc. | Automated control of cell growth rates for induction and transformation |
WO2019200004A1 (en) * | 2018-04-13 | 2019-10-17 | Inscripta, Inc. | Automated cell processing instruments comprising reagent cartridges |
US10501738B2 (en) | 2018-04-24 | 2019-12-10 | Inscripta, Inc. | Automated instrumentation for production of peptide libraries |
US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
US10526598B2 (en) | 2018-04-24 | 2020-01-07 | Inscripta, Inc. | Methods for identifying T-cell receptor antigens |
EP4070802A1 (en) | 2018-06-30 | 2022-10-12 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
US10752874B2 (en) | 2018-08-14 | 2020-08-25 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
US10532324B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
DE102018128723A1 (en) * | 2018-11-15 | 2020-05-20 | Endress+Hauser Conducta Gmbh+Co. Kg | Cuvette, preferably a flow-through cuvette for an optical measuring device and method for its operation |
US10907125B2 (en) | 2019-06-20 | 2021-02-02 | Inscripta, Inc. | Flow through electroporation modules and instrumentation |
CN114008070A (en) | 2019-06-21 | 2022-02-01 | 因思科瑞普特公司 | Whole genome rationally designed mutations leading to increased lysine production in E.coli |
US10927385B2 (en) | 2019-06-25 | 2021-02-23 | Inscripta, Inc. | Increased nucleic-acid guided cell editing in yeast |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
CN110511869B (en) * | 2019-08-08 | 2023-06-09 | 吉林大学 | Cell culture method and cell culture device capable of generating variable pulse electric field |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
US10689669B1 (en) | 2020-01-11 | 2020-06-23 | Inscripta, Inc. | Automated multi-module cell processing methods, instruments, and systems |
US11225674B2 (en) | 2020-01-27 | 2022-01-18 | Inscripta, Inc. | Electroporation modules and instrumentation |
IL295697A (en) | 2020-02-25 | 2022-10-01 | Inovio Pharmaceuticals Inc | Vaccines against coronavirus and methods of use |
US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
US11744885B2 (en) | 2020-05-14 | 2023-09-05 | Inovio Pharmaceuticals, Inc. | Vaccines for recurrent respiratory papillomatosis and methods of using the same |
US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
IL298874A (en) | 2020-06-12 | 2023-02-01 | Univ Rochester | ENCODING AND EXPRESSION OF ACE-tRNAs |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
TW202332694A (en) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | Serum half-life extended pd-l1 binding polypeptides |
TW202334196A (en) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1 binding polypeptides |
WO2023150753A1 (en) | 2022-02-07 | 2023-08-10 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0398960B1 (en) * | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
BE1004328A3 (en) * | 1990-05-16 | 1992-11-03 | Scient Equipment Design & Dev | METHOD AND DEVICE FOR LIVING CELLS permeabilization. |
US5185071A (en) * | 1990-10-30 | 1993-02-09 | Board Of Regents, The University Of Texas System | Programmable electrophoresis with integrated and multiplexed control |
US5545130A (en) * | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
US5422272A (en) * | 1993-07-14 | 1995-06-06 | Andrew A. Papp | Improvements to apparatus and method for electroporation |
US5869326A (en) * | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
-
1998
- 1998-10-21 US US09/176,136 patent/US6150148A/en not_active Expired - Fee Related
-
1999
- 1999-09-27 CN CN99812447.8A patent/CN1324398A/en active Pending
- 1999-09-27 WO PCT/US1999/022306 patent/WO2000023563A1/en active IP Right Grant
- 1999-09-27 DE DE69908631T patent/DE69908631T2/en not_active Expired - Fee Related
- 1999-09-27 CA CA002344325A patent/CA2344325A1/en not_active Abandoned
- 1999-09-27 EP EP99949889A patent/EP1121416B1/en not_active Expired - Lifetime
- 1999-09-27 AU AU62666/99A patent/AU6266699A/en not_active Abandoned
- 1999-09-27 AT AT99949889T patent/ATE242315T1/en not_active IP Right Cessation
-
2001
- 2001-09-20 US US09/957,891 patent/US20020068338A1/en not_active Abandoned
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080934A3 (en) * | 2004-04-19 | 2006-09-21 | Invitrogen Corp | Electroporation apparatus and methods |
US20060281182A1 (en) * | 2004-04-19 | 2006-12-14 | Invitrogen Corporation | Electroporation apparatus and methods |
WO2006080934A2 (en) * | 2004-04-19 | 2006-08-03 | Invitrogen Corporation | Electroporation apparatus and methods |
US11179269B2 (en) | 2006-09-26 | 2021-11-23 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US10292859B2 (en) | 2006-09-26 | 2019-05-21 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US11395760B2 (en) | 2006-09-26 | 2022-07-26 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US11219549B2 (en) | 2006-09-26 | 2022-01-11 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US9375345B2 (en) | 2006-09-26 | 2016-06-28 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US10383787B2 (en) | 2007-05-18 | 2019-08-20 | Zeltiq Aesthetics, Inc. | Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue |
US11291606B2 (en) | 2007-05-18 | 2022-04-05 | Zeltiq Aesthetics, Inc. | Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue |
US9655770B2 (en) | 2007-07-13 | 2017-05-23 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
US11583438B1 (en) | 2007-08-21 | 2023-02-21 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
US10675178B2 (en) | 2007-08-21 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
US9408745B2 (en) | 2007-08-21 | 2016-08-09 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
EP2254997A4 (en) * | 2008-02-20 | 2011-11-23 | Bio Rad Laboratories | Electroporation cuvette with spatially variable electric field |
EP2254997A1 (en) * | 2008-02-20 | 2010-12-01 | Bio-Rad Laboratories, Inc. | Electroporation cuvette with spatially variable electric field |
US9737434B2 (en) | 2008-12-17 | 2017-08-22 | Zeltiq Aestehtics, Inc. | Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells |
US9861520B2 (en) | 2009-04-30 | 2018-01-09 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US11452634B2 (en) | 2009-04-30 | 2022-09-27 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US8702774B2 (en) | 2009-04-30 | 2014-04-22 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US11224536B2 (en) | 2009-04-30 | 2022-01-18 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US9844461B2 (en) | 2010-01-25 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants |
US20110238051A1 (en) * | 2010-01-25 | 2011-09-29 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associated devices, systems and methods |
US9314368B2 (en) | 2010-01-25 | 2016-04-19 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods |
US10092346B2 (en) | 2010-07-20 | 2018-10-09 | Zeltiq Aesthetics, Inc. | Combined modality treatment systems, methods and apparatus for body contouring applications |
US8676338B2 (en) | 2010-07-20 | 2014-03-18 | Zeltiq Aesthetics, Inc. | Combined modality treatment systems, methods and apparatus for body contouring applications |
US9844460B2 (en) | 2013-03-14 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same |
US9545523B2 (en) | 2013-03-14 | 2017-01-17 | Zeltiq Aesthetics, Inc. | Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue |
US10806500B2 (en) | 2014-01-31 | 2020-10-20 | Zeltiq Aesthetics, Inc. | Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments |
US10575890B2 (en) | 2014-01-31 | 2020-03-03 | Zeltiq Aesthetics, Inc. | Treatment systems and methods for affecting glands and other targeted structures |
US11819257B2 (en) | 2014-01-31 | 2023-11-21 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US9861421B2 (en) | 2014-01-31 | 2018-01-09 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US10201380B2 (en) | 2014-01-31 | 2019-02-12 | Zeltiq Aesthetics, Inc. | Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments |
US10912599B2 (en) | 2014-01-31 | 2021-02-09 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US10675176B1 (en) | 2014-03-19 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Treatment systems, devices, and methods for cooling targeted tissue |
USD777338S1 (en) | 2014-03-20 | 2017-01-24 | Zeltiq Aesthetics, Inc. | Cryotherapy applicator for cooling tissue |
US10952891B1 (en) | 2014-05-13 | 2021-03-23 | Zeltiq Aesthetics, Inc. | Treatment systems with adjustable gap applicators and methods for cooling tissue |
US10568759B2 (en) | 2014-08-19 | 2020-02-25 | Zeltiq Aesthetics, Inc. | Treatment systems, small volume applicators, and methods for treating submental tissue |
US10935174B2 (en) | 2014-08-19 | 2021-03-02 | Zeltiq Aesthetics, Inc. | Stress relief couplings for cryotherapy apparatuses |
US11154418B2 (en) | 2015-10-19 | 2021-10-26 | Zeltiq Aesthetics, Inc. | Vascular treatment systems, cooling devices, and methods for cooling vascular structures |
EP3397335A4 (en) * | 2015-12-28 | 2018-12-26 | Inovio Pharmaceuticals, Inc. | Electroporation device with improved signal generator |
RU2750970C1 (en) * | 2015-12-28 | 2021-07-07 | Иновио Фармасьютикалз, Инк. | Electroporation device with advanced signal generator |
EP4098315A1 (en) * | 2015-12-28 | 2022-12-07 | Inovio Pharmaceuticals, Inc. | Electroporation device with improved signal generator |
WO2017117251A1 (en) * | 2015-12-28 | 2017-07-06 | Inovio Pharmaceuticals, Inc. | Electroporation device with improved signal generator |
CN108472482A (en) * | 2015-12-28 | 2018-08-31 | 艾诺奥医药品有限公司 | electroporation device with improved signal generator |
US10524956B2 (en) | 2016-01-07 | 2020-01-07 | Zeltiq Aesthetics, Inc. | Temperature-dependent adhesion between applicator and skin during cooling of tissue |
US10765552B2 (en) | 2016-02-18 | 2020-09-08 | Zeltiq Aesthetics, Inc. | Cooling cup applicators with contoured heads and liner assemblies |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
US10555831B2 (en) | 2016-05-10 | 2020-02-11 | Zeltiq Aesthetics, Inc. | Hydrogel substances and methods of cryotherapy |
US10682297B2 (en) | 2016-05-10 | 2020-06-16 | Zeltiq Aesthetics, Inc. | Liposomes, emulsions, and methods for cryotherapy |
US11466242B2 (en) | 2016-06-30 | 2022-10-11 | Zymergen Inc. | Apparatuses and methods for electroporation |
US10731121B2 (en) | 2016-06-30 | 2020-08-04 | Zymergen Inc. | Apparatuses and methods for electroporation |
US11076879B2 (en) | 2017-04-26 | 2021-08-03 | Zeltiq Aesthetics, Inc. | Shallow surface cryotherapy applicators and related technology |
US11446175B2 (en) | 2018-07-31 | 2022-09-20 | Zeltiq Aesthetics, Inc. | Methods, devices, and systems for improving skin characteristics |
WO2022106202A1 (en) * | 2020-11-17 | 2022-05-27 | Bühler AG | Device for treating cells in a bypass |
EP4001396A1 (en) * | 2020-11-17 | 2022-05-25 | Bühler AG | Device for treating cells in a bypass |
Also Published As
Publication number | Publication date |
---|---|
EP1121416B1 (en) | 2003-06-04 |
WO2000023563A1 (en) | 2000-04-27 |
AU6266699A (en) | 2000-05-08 |
EP1121416A1 (en) | 2001-08-08 |
CN1324398A (en) | 2001-11-28 |
DE69908631T2 (en) | 2004-04-01 |
CA2344325A1 (en) | 2000-04-27 |
ATE242315T1 (en) | 2003-06-15 |
US6150148A (en) | 2000-11-21 |
DE69908631D1 (en) | 2003-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6150148A (en) | Electroporation apparatus for control of temperature during the process | |
US5869326A (en) | Electroporation employing user-configured pulsing scheme | |
EP0785987B1 (en) | Flow through electroporation apparatus and method | |
US7245963B2 (en) | Electrode assembly for constant-current electroporation and use | |
US5318514A (en) | Applicator for the electroporation of drugs and genes into surface cells | |
US6027488A (en) | Flow-through electroporation system for ex vivo gene therapy | |
EP1140283B1 (en) | Method and apparatus for a combination of electroporation and iontophoresis for the delivery of drugs and genes | |
AU2009251157B2 (en) | Electrode assembly for constant-current electroporation and use | |
CA2497649A1 (en) | Apparatus and method for streaming electroporation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |